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To Friends of the Department of Medicine:
The Thomas Jefferson University Hospital Internal Medicine Residency Program was
informed this past February by the RRC that it has received Continued Accreditation
with a 5 year cycle length – the longest cycle length awarded for compliance with
essential elements of training in Internal Medicine as mandated by the ACGME.
The program’s next visit will be in 2015. This is the third straight highly successful
accreditation review for the program and the third straight 5 year cycle awarded.
The success of the recent visit should be attributed to our wonderful housestaff and
superb educational organization including:
Our amazing office staff: Joanne Gotto (Education Manager), Debbie Richards (Program
Coordinator), Fortune Medeiros (Dr. Kane’s Assistant), and Brenda Merlino.
Our committed Associate and Assistant Program Directors: Drs. Gretchen Diemer,
Mark Graham, Sal Mangione, Elisabeth Carr, Jessica Salt, and Donna Williams.
Our talented Chief Residents: Drs. Assis, Moleski, Fisicaro (2008-2009), & Drs. Hess,
Patel, Serper, and Nolt (2009-2010), as well as those of prior years.
While those elements are vital; the commitment of our Chairman, Arthur M. Feldman,
MD PhD, to the educational mission at Jefferson is the essential ingredient to the
training of gifted Internists for careers in academics and patient care. Under his
leadership, our clinical programs and research activity have expanded and excelled;
creating a fertile environment to support the growth of our students, residents,
and fellows. All of our faculty are to be congratulated for their contributions to the
education of our trainees, as their work, day in and day out, provides the daily attention
necessary for the health of all of our programs.
While accreditation itself is an important goal; the main objective of our program is
to train outstanding physicians for practice, research, and education. Achieving full
accreditation allows us to pursue many of the innovative programs and projects that
truly define the excellence of our Department and our Residents. One such project is
the publication of this journal. Our Editors should be proud indeed of the work of their
contributors and of their own effort in organizing and editing this edition. It is yet one
more way we enhance the educational and academic environment at Jefferson!
Of all the important things we do as academic physicians – the discovery of new
scientific knowledge, the conduct of important clinical trials, service to national medical
organizations, or the delivery of advanced patient care; contributing to the knowledge
and skill of the Internists of Tomorrow is among the most satisfying; given the
personal connections we have with our trainees and the future impact of these young
physicians in the years ahead. Jefferson’s reputation as a leader in research, patient care,
and education continues to grow. The success of our training programs reflects the
excellence of the institution and of our human capital.
We hope you’ll enjoy this issue of the Forum and congratulate each of the contributors
as they cross your path.

Gregory C. Kane MD, FACP, FCCP
Professor of Medicine
Residency Program Director and Vice-Chairman
Interim Chief, Division of Pulmonary and Critical Care
Department of Medicine
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As the Jefferson Forum embarks on its 11th issue a number of additions have been
instituted. First, we are proud to announce new faculty collaborators with Dr. Steven
Herrine, Dr. Danielle Duffy, Dr. Daniel Frisch, Dr. Anjali Avadhani, Dr. Joseph
Desimone and Dr. Edward Ruby.
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Our faculty has helped us with creating a new section of outstanding articles that
we introduce in this issue. The “Best Of” designation allows us to highlight articles
that were chosen by peer and faculty review as the best example of academic work
submitted in each field of medicine. We hope that this addition will inspire more
residents and faculty to get involved with the journal.
In addition, as residents graduate and embark on their individual academic journeys,
we hope they remain connected to the forum by contributing their knowledge and
expertise. We believe that in this issue a new level of excellence has been achieved
and that could not be accomplished without our outstanding residents. We hope you
enjoy this issue and look forward to the next one!
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Best of Gastroenterology

Acute Pancreatitis with Normal Amylase and Lipase
Kichul Ko, MD, Luz Catherine Tello, MD, Jessica Salt, MD
Introduction

Acute pancreatitis is diagnosed by clinical history and physical
examination with concurrent elevations in serum amylase and
lipase levels; occasionally radiographic findings are of further
assistance. We report a case of radiographically proven acute
pancreatitis with normal serum amylase and lipase levels.

Case Report

A 35 year old male patient was in his usual state of health until
four days prior to presentation when he began experiencing
severe epigastric abdominal pain accompanied by nausea
and vomiting. On Day 2 of his symptoms, he reported to
the emergency department and was discharged home with
a diagnosis of viral gastroenteritis. His symptoms worsened
causing his return to the emergency department the following
day for re-evaluation. The patient’s past medical history
included recently diagnosed diabetes mellitus type 2 and
gastroesophageal reflux disease (GERD). His medications
included metformin and esomeprazole which he took for the
first time on Day 1 of symptom onset and did not continue
taking secondary to severe nausea and vomiting. He had no
known drug allergies. He reported occasional use of alcohol
with the last use about two months prior to this presentation.
He smoked one and a half packs of cigarettes per day for 14
years. He denied any past or present illicit substance use. He
reported no personal or family history of pancreatitis.
His admission laboratory findings were: WBC count 19.8 x
109 B/L with 11% bands, hemoglobin 13.3 g/dL, platelets 282
x 109 /L, creatinine 1.1 mg/dL, aspartate aminotransferase 16
IU/L, alanine aminotransferase 24 IU/L, alkaline phosphatase
78 IU/L, lactate 23.1 mg/dL, triglyceride 1195 mg/dL, amylase
17 IU/L (normal <132) and lipase 25 IU/dL (normal <52). A
CT scan of the abdomen revealed diffuse fatty liver infiltration,
homogenously enhancing pancreas and significant peripancreatic infiltration with surrounding fluid consistent with a
diagnosis of acute pancreatitis. It also showed gallstones with no
ductal dilation. The abdominal ultrasound showed cholelithiasis
with no evidence of cholecystitis.
Based on the clinical presentation and radiographic findings,
the patient was diagnosed with acute pancreatitis secondary
to hypertriglyceridemia. He was treated with bowel rest,
hydration, and pain control. The patient was also found to have
pneumonia which was treated with moxifloxacin. Gemfibrozil
and simvastatin were added for his dyslipidemia. His symptoms
continued to improve during the hospital course and he
was discharged on Day 7 with medications for pain control,
dyslipidemia, diabetes, GERD and pneumonia.

Discussion

The diagnosis of acute pancreatitis is made based on relevant
clinical features including severe abdominal pain, nausea,
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vomiting and elevation of pancreatic enzymes with serum
amylase and/or lipase levels usually three times the upper limit
of normal.1,2 Abdominal imaging with CT, magnetic resonance
imaging (MRI), or transabdominal ultrasonograph (US) can be
helpful in confirming the diagnosis of pancreatitis or ruling out
other etiologies of acute abdominal pain that may cause mild
elevations of serum pancreatic enzymes1.
Lipase is a 48 kD pancreatic enzyme that is involved in
digestion. Lipase level increases within four to eight hours of
acute pancreatitis, peaks at 24 hours, and remains elevated
for one to two weeks, typically longer than amylase levels1,3,4.
Lipase is more sensitive and specific than amylase in diagnosing
acute pancreatitis, with a negative predictive value of 94% to
100%3,4. Therefore, normal lipase level in the setting of acute
abdominal pain is often used to rule out a diagnosis of acute
pancreatitis. Our patient was admitted with a clinical picture
and radiographic findings consistent with acute pancreatitis
despite normal lipase and amylase levels throughout the hospital
course. In the case of our patient, the etiology of acute pancreatis
was hypertriglyceridemia. Previous studies suggested that
the hyperlipemic serum may interfere with the amylase assay
in vitro leading to false negative results.5 However, there have
been no previous reports on the effect of serum triglyceride
on lipase level analysis. A literature search yielded two cases of
symptomatic acute pancreatitis with normal lipase levels similar
to our patient, however, neither reported the likely etiology for
acute pancreatitis3,4. While it is possible that this presentation
was an acute-on-chronic attack secondary to longstanding
pancreatitis caused by hypertriglyceridemia, this is an unlikely
explanation based on clinical and radiographic findings. This
was the first reported symptomatic occurrence of pancreatitis in
this patient and the radiographic findings did not reveal calcifications or fibrosis in the pancreas that is commonly associated
with chronic pancreatitis.
This is an unusual case of acute pancreatitis with normal amylase
and lipase levels in the setting of hypertriglyceridemia. This case
highlights that while laboratory findings are useful diagnostic
criteria, the absence of such findings should not replace clinical
judgment used in formulating most appropriate diagnosis.
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Best of Cardiology

Perioperative Beta-Blockers: Where do we stand?
Li Shien Low, MD, Jennifer Heckman, MS III, Matthew DeCaro, MD
Introduction

Cardiovascular disease is a significant cause of morbidity
and the leading cause of mortality in both the United States
and worldwide.1,2 Given the considerable burden of disease,
cardiac risk assessment is an especially important element
of preoperative evaluation prior to noncardiac general
surgery.3 Globally, an estimated 100 million adults undergo
noncardiac surgery each year,4 more than one third of whom
have underlying coronary artery disease (CAD). 5 Cardiac
complications, including cardiac death, nonfatal myocardial
infarction (MI), and nonfatal cardiac arrest, represent major
causes of peri- and postoperative morbidity and mortality. 6
The incidence of such cardiac complications is an estimated
1.4% in relatively unselected patients,7 with an even greater
incidence (2.4 – 5.8%) among those with or at risk of cardiac
disease. 8,9,10,11,12,13 Annually, more than one million patients
are likely to experience such a complication.6 The magnitude
of this problem can be measured not only in patient health
outcomes and illness burden, but also in terms of the large cost
subsequently imposed upon the healthcare system, especially as
the number of noncardiac surgical patients at risk for adverse
cardiac outcomes continues to increase.14
A common underlying pathophysiology posited to mediate
perioperative myocardial infarctions is atherosclerotic plaque
disruption, which leads to coronary vessel obstruction,15 as well
as prolonged ischemia.16 Perioperative myocardial ischemia is a
consequence of an exaggerated sympathetic response, evidenced
by increased myocardial oxygen demand and decreased
coronary diastolic filling time (secondary to increases in heart
rate and contractility caused by physiologic stress and elevated
catecholamine levels).17
The exact mechanism by which beta-blockers reduce
perioperative cardiac complications remains unclear. It has been
proposed that through attenuation of the sympathetic response,
with the major effects of reduction in heart rate (leading to
increased perfusion time) and contractility (leading to decreased
oxygen demand), perioperative beta-blockade results in a
reduction in both cardiac caused mortality and the incidence
of cardiovascular complications.18 Another hypothesis is that
it is optimal heart rate control, rather than a specific agent,
that is associated with a decline in ischemic events, as cardiac
damage often results from inadequate myocardial blood flow.16
Additional potential cardiovascular effects of perioperative beta
blockade include “vulnerable” coronary plaque stabilization and
dysrhythmia prophylaxis.19

Perioperative Beta-Blockade: Evolution of the Evidence

Initial randomized trials, including the landmark study on which
the original 1996 American College of Cardiology/American
Heart Association (ACC/AHA) recommendations20 were based,

suggested that beta-blockers reduce perioperative ischemia in
patients with underlying arterial disease. 18 Mangano et al 18
performed a randomized, double-blind, placebo-controlled
study comparing the effects of atenolol with those of a placebo
on overall survival and cardiovascular morbidity in individuals
undergoing noncardiac surgery with coronary artery disease
(history of MI, typical angina, or atypical angina with positive
stress test result) or risk factors for coronary artery disease (≥2
of the following: age >65 years, hypertension, current smoker,
cholesterol level >240 mg/dL, or diabetes). Results of this
study of 200 patients demonstrated that, in this population,
perioperative atenolol (administered intravenously 30 minutes
prior to surgery and continued by mouth throughout the hospital
stay for up to 7 days) significantly reduced overall mortality
and incidence of cardiovascular complications for as long as
two years following discharge, with the primary effect identified
as a decrease in mortality from cardiac causes during the first
six to eight months. Atenolol administration, however, did not
significantly reduce cardiac causes of mortality during hospitalization or incidence of perioperative MI. This lack of effect of
atenolol in the perioperative period, however, may have been a
result of the low incidence of significant perioperative cardiac
events among study population patients, thus demonstrating a
potential limitation of the study.
Subsequent research continued to contribute to a mounting body
of evidence supporting perioperative beta-blockade in patients
undergoing noncardiac surgery at high risk for adverse cardiac
outcomes. In 1999, the Dutch Echocardiographic Cardiac Risk
Evaluation Applying Stress Echocardiography (DECREASE)
Study Group21 reported a randomized, non-blinded, placebocontrolled, multi-center trial examining the effect of bisoprolol
on perioperative mortality and myocardial infarction in a
subgroup of high-risk patients undergoing vascular surgery.
High-risk patients were identified by the presence of both
clinical risk factors and dobutamine stress echocardiography
results positive for ischemia. Subjects were randomized and
treatment group patients received standard perioperative care
plus bisoprolol (initial dose at least one week prior to surgery
and continued for thirty days postoperatively, with subsequent
dosing individually adjusted by physician based on heart rate).
Study endpoints were defined as cardiac death and myocardial
infarction. A majority of the adverse cardiac events in both
groups occurred during the first seven days following surgery.
Overall study findings indicated a reduction in perioperative
incidence of cardiac causes of mortality and nonfatal MI with
the perioperative administration of bisoprolol. Despite the
lack of significant clinical and echocardiogram differences
between the standard care and treatment groups, the combined
incidence of cardiac events in the standard care group was
34%, compared to 3.4% in the bisoprolol group. This striking
difference demonstrated a substantial benefit to treatment,
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significant enough to cause the investigation safety committee
to suspend the study.
Based on investigation results, the DECREASE Study Group
recommended that high-risk surgical patients receive
beta-blockers perioperatively, with initiation one to two weeks
preoperatively and continuation for at least two weeks postoperatively, with a goal of heart rate reduction to <70 beats/
minute preoperatively and <80 beats/minute in the immediate
postoperative period. Investigators also suggested a potential
alternative approach to standard preoperative management,
proposing exclusion of preoperative non-invasive cardiac
testing and replacement with prescription of perioperative
beta-blockade for all patients with clinical risk factors undergoing
high-risk surgery. Major limitations of this study were the fact
that it was not blinded, thus allowing for potential bias and
reporting error, and its focus only on a specific subpopulation.21
Prevention of perioperative morbidity and mortality is not the
only consideration in the initial preoperative evaluation of a
patient. Also important is the assurance of long-term future
survival. As such, a related, follow-up study by the DECREASE
Study Group22 assessed the long-term cardioprotective effects
of perioperative and prolonged postoperative beta-adrenergic
blockade with bisoprolol in the same, randomized cohort
of high-risk patients following successful major noncardiac
vascular surgery. Again, study treatment dosage was adjusted by
physicians based on prescribed heart rate guidelines. Two-year
follow-up was complete in all patients, monitoring for the
occurrence of late cardiac events, including cardiac death and
myocardial infarction. With no significant differences in clinical
characteristic between the treatment and control groups,
combined perioperative and long-term postoperative bisoprolol
administration resulted in a significant, three-fold decrease in
the incidence of late cardiac death and MI among high-risk
patients after surviving major vascular surgery. However, similar
to the previous study, patients and physicians were not blinded
to the treatment. In addition, pre-trial risk of cardiac events
in the two study groups may not have been comparable; the
standard treatment group included survivors of perioperative
MI, who may have consequently been at increased risk of late
cardiac events during follow-up, and elevated incidence of
perioperative mortality in the standard treatment group may
also have eliminated the highest risk patients in this group.
Further trials evaluating the use of perioperative beta-blockers
in patients undergoing noncardiac surgery did not produce
favorable results, which challenges their efficacy and safety.
Randomized controlled trials, including the Diabetic
Postoperative Mortality and Morbidity (DIPOM) trial23 and the
Metoprolol after Vascular Surgery (MaVS) study,24 demonstrated
a lack of benefit of perioperative beta-blockade among specific
patient populations, though there were limitations in the
designs of these trials. More notably, the recent POISE trial,25
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a large, multinational, multicenter, randomized, double-blind,
placebo-controlled trial, was conducted to investigate the effects
of perioperative beta-blockers in patients with risks for atherosclerosis or known atherosclerosis undergoing noncardiac
surgery. Patients were randomized to receive either placebo
or extended-release metoprolol succinate, which was initiated
two to four hours prior to surgery and continued for 30 days
postoperatively. Intention to treat analysis was conducted on
a population of 8351 patients, and the primary endpoint was
a composite of cardiovascular death, non-fatal myocardial
infarction, and non-fatal cardiac arrest. At follow-up 30 days
postoperatively, while significantly fewer treatment group
patients reached the primary endpoint (an outcome driven
entirely by a significant reduction in MI among treated patients),
the incidences of both death and stroke were significantly
greater in the metoprolol group. Though other factors may be
responsible, investigators associated these findings primarily to
the clinically significant hypotension and bradycardia associated
with beta-blockade. Subsequent meta-analyses of trials of
perioperative beta-blockers including POISE revealed some
similarities in results and consistency with POISE findings.
Meta-analyses demonstrated a risk reduction in non-fatal MI
with beta-blockade, but also suggested an increased risk of death
and non-fatal stroke with use of perioperative beta-blockers.
The POISE study represents the largest trial conducted to date
addressing perioperative beta-blockers in patients undergoing
noncardiac surgery. It is important to recognize, however,
that this study too has its limitations. This trial utilized a very
high and fixed dose of metoprolol (initial dose 2-8 times the
commonly prescribed dose with no adjustment for heart
rate). Additionally, therapy was initiated shortly (only hours)
before surgery. Also of note is that in all of the meta-analyses
conducted, POISE data accounted for approximately 80% of
the patients. Results do, however, underscore the potential risks
underlying the assumption that perioperative beta-blockade is
beneficial and without harm.

Evidence Limitations

The role of beta-blockers in the perioperative setting is not
yet clearly defined. Few randomized trials of medical therapy
to prevent major perioperative adverse cardiac events have
been performed, and most trials do not have sufficient power.
Despite evidence from some trials demonstrating the potential
benefit of perioperative beta-blockade in high-risk patients,
much controversy still surrounds their use, especially given the
methodological limitations of prior studies. No single agent,
dose, route of administration, dosing schedule, or duration of
treatment has been shown to be most effective. In addition, few
studies have examined the effect of titration of therapy (i.e., to
a target heart rate). Other controversial issues include the use
of long- versus short-acting agents, effects of beta-blockade in
patients on chronic beta-blocker therapy prior to surgery versus
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beta-blocker naive patients, and genetic variability in response
to beta-blockade. 26 Future research should aim to identify
the optimal beta-blocking agent as well as define the role of
perioperative beta-blockade in intermediate- and low-risk
populations. To date, no literature has addressed the important
topic of care-delivery mechanisms in the perioperative setting,
identifying how, when, and by whom perioperative beta-blocker
therapy should be implemented and monitored. More evidence
is needed to corroborate the findings of previous studies and
provide future direction. Further study will contribute to
improved understanding, elucidation of these issues, and better
clinical application of the available data.

Current Guidelines

While POISE trial investigators concluded a need for revision of the
approach to the use of perioperative beta-blockers, current ACC/
AHA guidelines,27 published in 2006, which include a focused
update on perioperative beta-blocker therapy, still endorse a
relatively wide indication for perioperative beta-blockade. Class
I recommendations include: 1) continuation of beta-blockers in
patients undergoing surgery who are prescribed beta-blocker
therapy for angina, symptomatic arrhythmias, hypertension, or
other ACC/AHA Class I guideline indications, and 2) administration of beta-blockers to patients undergoing vascular surgery
at high cardiac risk with ischemia on preoperative testing. In
addition, based on Class IIa recommendations, beta-blockers
are probably recommended for 1) patients undergoing vascular
surgery with evidence of coronary heart disease on preoperative
testing, 2) patients in whom preoperative evaluation for
vascular surgery identifies high cardiac risk, and 3) patients in
whom preoperative assessment identifies coronary heart disease
or high cardiac risk and who are undergoing intermediate- to
high-risk procedures. According to Class IIb recommendations,
beta-blockade may also be considered for 1) patients who are
undergoing intermediate- or high-risk procedures in whom a
single clinical cardiac risk factor is identified preoperatively,
and 2) patients undergoing vascular surgery with low cardiac
risk not currently on beta-blockers.
Though an approach to documenting cardiac risk different
from the AHA/ACC guidelines, the Revised Cardiac Risk Index
(RCRI)7 is another extensively tested and accurate estimate of
risk that can be utilized to guide care.28 The RCRI accounts for six
variables: 1) high risk type of surgery, 2) ischemic heart disease,
3) history of congestive heart failure, 4) history of cerebrovascular disease, 5) insulin-dependent diabetes mellitus, and
6) chronic renal insufficiency (preoperative serum creatinine
>2.0 mg/dL). Based on this method of preoperative risk stratification, subsequent risk of major cardiac complications with
noncardiac surgery is estimated as illustrated in Figure 1, with
and without beta-blocker therapy.28

Figure 1.
Risk
Stratification
Low Risk

RCRI
criteria

Risk without
adrenergic
blockade (%)

Risk with
beta-blockade
(%)

0

0.4-1.0

<1

Intermediate
Risk

1-2

2.2-6.6

0.8-1.6

High Risk

≥3

>9

>3

Where Do We Go From Here?

What, then, are the consequences of the results of the POISE trial
for the use of perioperative beta-blockers in clinical practice? In
using the treatment regimen outlined by the DECREASE Study
Group, a low-dose, long-acting agent titrated to effect at least 7
days prior to surgery, a greater overall benefit to perioperative
beta-blockade is seen as compared to risk. The POISE trial,
however, demonstrates that acute administration of high-dose
beta-blocker therapy may be associated with greater risk than
benefit. Given all of the data, we do not believe that the evidence
supports the initiation of prophylactic perioperative beta-blocker
therapy in low- to intermediate risk patients (RCRI £2)
undergoing noncardiac surgery. While beta-blockers do appear
to decrease the risk of perioperative MI, the observed increases
in the rates of stroke and mortality likely outweigh this benefit.
A majority of the myocardial infarctions will be asymptomatic,
but a few will result in serious complications in the perioperative
period. In contrast, most strokes will be seriously disabling or
incapacitating. However, perioperative beta-blockade still likely
has significant cardioprotective effects in high-risk patients
(RCRI ≥3) or patients with evidence of significant ischemia by
preoperative evaluation. In these patients, use of a beta-blocker
perioperatively, with possible continuation in the postoperative
period seems most prudent, with additional consideration for
whether the patient is on chronic beta-blocker therapy prior to
surgery or is beta-blocker naïve. Beta-blockers should be started
orally days, if possible even weeks prior to the scheduled date of
surgery to allow gradual up-titration of the dosage to achieve
optimal heart rate and blood pressure control.

Conclusion

Cardiac complications of noncardiac surgery result in substantial
morbidity and mortality, posing a serious health problem,
whose magnitude only threatens to increase as the incidence of
CAD rises and the population ages. As such, an accurate tool
for cardiac risk assessment as well as sound guidelines for the
subsequent prevention of such adverse outcomes is essential in
moving forward. In select patients, perioperative beta-blockade
may provide a safe and effective method of cardioprotection.
However, it is crucial to highlight that as per the POISE trial,
initiating perioperative beta-blockade is not without its own set
of complications. Therefore, identification of the appropriate
target population, avoidance of the adverse outcomes of
such drugs, and future research aimed at characterizing the
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appropriate therapeutic regimen are needed in order to achieve
the goal of reduced morbidity and mortality.
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A Case of an Atypical, Community Acquired Pneumonia:
A Case Summary and Topic Review
David P. Cork MS IV, Joanne Kim MD, Jie Cui, MD
Case Report

A 59 year old gentleman with a past medical history of
hypertension, hyperlipidemia, anxiety, depression, arthritis,
and hypothyroidism presented with a five day history of fever
to 102º F. He complained of a three-day history of nausea,
vomiting, and non-bloody, loose diarrhea, all of which had
been persistent and worsening over the past week. Over the
past two days, the patient had felt short of breath, and presented
in a state of severe dyspnea. He had experienced an indolent
course of illness, but was now concerned with his tachynpea and
wheezing, and he had developed a productive cough with a small
amount of yellow-brown sputum. He denied any hemoptysis
as well as recent travel or sick contacts. On admission, the
patient was taking hydrochlorothiazide, lisinopril, atorvastatin,
levothyroxine and fluoxetine. He was also using over-thecounter ibuprofen for arthritic pain.

Figure 1. Imaging upon admission
Chest x-ray – A bilateral infiltrative process is seen consuming the
majority of the right lung.

The patient was a smoker with a ten pack-year history. He
denied intravenous drug use and occasionally drank alcohol.
Family history was significant for paternal obstructive lung
disease and coronary artery disease. On review of systems, the
patient denied having a sore throat or any nasal congestion.
Vital signs upon presentation were temperature 101.0º F,
pulse 110 beats per minute, respiratory rate 40 breaths per
minute, blood pressure 125/68 mmHg, and pulse oximetry of
86% on a non-rebreather mask. Upon physical examination,
the patient was in moderate respiratory distress and unable to
talk in complete sentences. He appeared mildly confused, but
was awake, alert, and oriented. Jugular venous distention was
not recognized. His cardiovascular exam was significant for
tachycardia, but was without murmurs, rubs, or gallops. His
pulmonary exam demonstrated coarse breath sounds bilaterally
with diffuse, rhonchi throughout all lung fields. His abdomen
was soft, mildly distended with moderate obesity, and was
without hepato-splenomegaly. He had no lower extremity
edema and his musculoskeletal exam was grossly normal. His
skin was warm and moist, with good capillary refill (<2 sec).
Laboratory studies upon admission demonstrated electrolyte
abnormalities, including a sodium of 125 mmol/L, chloride of
91 mmol/L, blood urea nitrogen of 83 mmol/L and creatinine of
5.6 mmol/L. His complete blood count was within normal limits.
Blood gas demonstrated a pH of 7.22 carbon dioxide pressure of
45 mmHg, and oxygen pressure of 69 mmHg. Cardiac enzymes
were negative and brain natriuretic peptide was 43.9 ng/L.
His coagulation studies were within normal limits, as was his
thyroid stimulating hormone. A urinalysis showed a slightly
cloudy specimen with mild proteinuria. Clostridium difficile
antigen was negative.
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Figure 2. CT Chest without contrast – As the images move
superiorly to inferiorly, note the dense consolidation of the right
upper and lower lobes, as well as the groundglass appearance to
the infiltrative process of the left upper lobe.
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The patient was intubated in the Emergency Department due
to severe dyspnea, hypoxia, and respiratory failure. Blood,
urine and stool cultures were obtained. The patient was started
on empiric antibiotic coverage for signs of possible systemic
inflammatory response system with consolidative pneumonia
with pipercillin-tazobactam, vancomycin, and azithromycin.
Given the patient’s history of diarrhea, dyspnea, mild confusion,
and hyponatremia, a Legionella urine antigen was also sent. The
patient was admitted to the medical Intensive Care Unit, and
nephrology and infectious disease services were consulted.
The patient’s urine Legionella antibody assay returned positive,
and antibiotic coverage was then narrowed to azithromycin.
Treatment was planned for 21 days. After nine days of ventilatory
support, the patient was weaned and extubated without
complication. Upon questioning, the patient explained that he
had recently been working to remodel his bathroom, including
removing a finished bath tub which was designed to lay a top
the previous tub. The oldest tub was full of stagnate water which
had been pooled there for approximately six months before this
planned bathroom remodel. This added a potential source of
Legionella infection to the overall clinical story.

Figure 3. CXR upon extubation – There has been interval
clearance of the infiltrative process of the right lung. Residual
patchy infiltrates remain in the left lung base and right middle
and lower lobes.

Introduction to Legionella and Legionnaire’s Disease
Background

First identified in Philadelphia in 1976, Legionella has become
recognized as a common atypical pathogen. Legionella
is ubiquitous and classified as a fastidious gram-negative
coccobacilli, representing a genus with over fifty subgroups.
L. pneumophila comprises at least sixteen different subgroups,
many of which require very specific culture growth media.
Legionellosis refers to two clinical syndromes caused by the
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genus Legionella: 1) Legionnaire’s disease, a syndrome of
pneumonia, and 2) Pontiac fever, an acute febrile illness that
tends to be self-limited in nature.

Epidemiology

Legionella is noted as one of the top four causes of community
acquired pneumonia (CAP) amongst the immunocompromised
population, and is a common culprit of hospital-associated
pneumonia. In fact, the incidence of Legionella as a cause of
sporadic community-acquired pneumonia ranges from 2-15%
of all cases requiring admission to a hospital.�

Transmission of Disease

Transmission of Legionella is accomplished by way of aerosol
inhalation or by micro-aspiration of water contaminated with
the organism.1 Cooling towers, ultrasonic mist machines such
as those used by grocery stores, respiratory equipment, and
whirlpool baths have been commonly cited as vectors for disease
transmission. Water distribution systems in nursing homes,
workplaces, and private residences have each been implicated as
primary sources of Legionellosis. Indeed, potable water sources
have been associated with numerous reports of Legionella
infection. The species L. pneumophila is capable of infecting and
replicating in various protozoa found in soil and water, and may
have increased virulence if replication occurs within amoeba.1
Due to L. pneumophila’s virulence, Legionella pneumonia is
recognized as manifesting a more severe pneumonia than other
bacteria commonly associated with CAP.
The group of atypical CAP represents systemic infectious diseases
that can primarily or secondarily infect the lungs. Atypical CAP
differs from CAP in the way the specific bacteria infect host
cells. Atypical bacteria are facultative intracellular organisms
most susceptible to tetracylines, macrolides, or quinolones.
Indeed, Legionella species are capable of exponential multiplication within human monocytes and alveolar macrophages.
An intact cellular immune response is thus necessary to inhibit
intracellular replication, with use of activated macrophage and
monocyte cell-mediated immunity. Patients with immunesuppression have neutrophil ingestion of the organisms
after complement and antibody have targeted the organism,
but often are unable to effectively kill the bacteria. 2 Typical
pneumonias more commonly are comprised of organisms that
invade interstitial spaces between cells and trigger neutrophil
activation with cytokine release, thereby activating a generalized
and immediate immune response.

Risk Factors and Disease Manifestations

Underlying disease is a major risk factor for acquisition of this
disease. The risk factors most commonly implicated are cigarette
smoking, chronic lung disease, and immunosuppression.
Severely immunocompromised patients are said to fare worse
in terms of disease severity, which may include lung abscess and
bacteremia. They are also at risk for extra-pulmonary infections
including sinusitis, pancreatitis, peritonitis, pyelonephritis, and
most commonly, cardiac manifestations such as myocarditis,
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Table 1. Common Clinical Features of Legionnaire’s Disease
Organ Involved

Common Features

Argues Against Legionnaires’ Disease

Central Nervous System

Confusion

Meningeal Signs

Upper Respiratory Tract

None

Sore throat, ear pain, bullous myringitis, otitis media

Cardiac

Relative bradycardia

Splenomegaly

Gastrointestinal

Loose, watery stools

Hepatic tenderness, RLQ pain, LUQ tenderness,
peritoneal signs

Renal

Renal insufficiency

CVA tenderness, chronic renal failure

pericarditis, postcardiotomy syndrome, and endocarditis
(Table 1).3 Nasogastric tubes have been implicated as sources
of nosocomial legionellosis as well.1 Also, patients who have
recently undergone head and neck surgery, and therefore
are susceptible to aspiration, have been noted as an at-risk
population.1 Common clinical features of community-acquired
pneumonias include: cough, fever, pleuritic chest pain, sputum
production, and dyspnea. Scant sputum production is more
typical of atypical community-acquired pneumonias, whereas
typical pneumonias contracted within the community are more
commonly characterized by mucopurulent sputum production.

Differential Diagnosis

• Chlamydia pneumonia
• Mycoplasma pneumonia
• Fungal pneumonia
• Viral pneumonia
• Q Fever
• Psittacosis

Owing to its potential degree of severity and its resistance
to beta-lactam antibiotic therapy, Legionella represents the
most important nonzoonotic CAP pathogen to differentiate
from CAP pathogens.2 With observation of commonalities
amongst patients infected with Legionella, it is possible to
make presumptive diagnoses based on clinical presentation.
Therefore, it is important to keep in mind the following differentiating features frequently seen with Legionella infection
when narrowing a differential diagnosis:
a. relative bradycardia in the context of a febrile illness
1. limits diagnosis to Legionella, Q fever, and psittacosis
b. unexplained mental confusion, including cerebellar ataxia
c. loose, watery stools

Clinical Diagnosis

Pneumonia is the predominant clinical syndrome. The disease
may represent a broad spectrum of illnesses though, ranging
from mild cough to respiratory failure. Typically seen early in
the disease course are non-specific symptoms and signs such as

fever, malaise, myalgias, headache, and anorexia.1 Cough tends
to be only slightly productive, and temperature commonly
exceeds 104º F. Diarrhea may be seen in approximately 25%
of cases, with complaints of watery rather than bloody stools;3
loose, watery diarrhea was reported in approximately 6% of other
types of community-acquired pneumonias. 3 Other common
characteristic findings are relative bradycardia, which is most
common among the elderly or those with advanced disease
states and hyponatremia (serum sodium levels less than 130
mg/dL). Additionally, in patients demonstrating an increased
cold agglutinin titer, which is commonly checked for suspected
mycosplasma infections, the diagnosis of Legionella pneumonia
is essentially ruled out. Due to the variance in severity of disease,
as well as specialized lab tests required to confirm the diagnosis,
Legionellosis is often underdiagnosed.5
The most important test for Legionnaire’s disease is the
isolation of the organism by culture on buffered charcoal yeast
extract. Obtaining adequate sputum for culture can often be
problematic in these patients however. When Legionnaire’s
is considered or suspected, a urine antigen test, Legionella
culture, and a direct fluorescent antibody (DFA) staining from
sputum or tissues should be considered. Indirect immunofluorescence assay (IFA) and/or enzyme-linked immunosorbent
assay (ELISA) are also possible, but are not as useful in clinical
decision making, as increased titers over four to eight weeks
are required for confirmatory diagnoses (a fourfold rise in
the titer of serum IgG antibody to L. pneumophila with final
titer of at least 1/128 is commonly considered positive). 6 The
urine antigen test is an enzyme immunoassay with sensitivity
of approximately 70%, and nearly 100% sensitivity;7 this test
however applies to L. pneumophila serotype 1, which represents
only 80-90% of Legionella infections.7 In contrast, the DFA test
(sensitivity 33-68%, specificity 99-100%) can be performed in a
manner of a few hours.8 ELISA tests are generally preferred over
IFA tests nowadays, due to reportedly improved sensitivities
(80% and 70%, respectively).8,9 Unfortunately this type of serum
testing also lacks sensitivity for detecting serotypes other than
serotype 1, as with the urine tests.

Treatment

Quinolones or doxycyline remain first-line therapy. Delay
in initiation of treatment significantly increases mortality.1
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Table 2. Non-Specific Laboratory Tests
Nonspecific Laboratory Tests

Common Features

Argues Against Legionaire’s Disease

Gram stain (sputum)

Few mononuclear cells, few/no bacteria

Purulent sputum, single predominant organism

White Blood Cell Count

Leukocytosis, relative lymphopenia

Leucopenia, thrombocytosis, thrombocytopenia

Pleural Fluid

Exudative

Red blood cells, decreased pH, decreased glucose

Aminotransferases

Mildly elevated (2-5x normal)

Markedly elevated (10x normal)

Serum Phosphorus

Decreased (early)

Normal value does not rule out Legionnaire’s Disease

Creatine Phosphokinase

Increased (early)

Normal value does not rule out Legionnaire’s Disease

C-Reactive Protein

Increased (early)

Normal value does not rule out Legionnaire’s Disease

Ferritin

Highly elevated (>2x normal)

Normal/slightly increased early. Normal value does not rule
out Legionnaire’s Disease

Cerebral Spinal Fluid

No pleocytes

Red blood cells, decreased glucose, decreased lactate

Urinalysis

Microscopic hematuria

Gross hematuria, pyuria, hemoglobinuria

Stool

Watery stools

Blood or mucus

Treatment duration is two weeks with quinolones, or two to
four weeks with other antibiotics.1 Another treatment option is
macrolides, however there is variability between drug efficacy in
this class for eradicating Legionella. For instance, erythromycin
has been associated with therapy failures.1 Other macrolides,
such as azithromycin are said to have better in vitro activity and
improved pulmonary tissue penetration.1 Overall, quinolones
have improved in vitro activity and intracellular penetration
compared to macrolides. In patients who are severely ill,
rifampin is recommended as an adjunct in combination therapy
with a macrolide or quinolone, as it has high levels of activity
against Legionella. Imipenem, trimethoprim-sulfamethoxazole,
and clindamycin have all been proven efficacious for the
treatment of Legionella pneumonia. 9 Treatment of the
underlying pneumonia will improve the associated diarrhea,
electrolyte abnormalities, and other associated syndromes seen
with Legionnaire’s Disease.

Prognosis

Patients with Legionnaire’s Disease usually experience
symptomatic improvement within three to five days if treated
early with an effective antibiotic. With early treatment and
appropriate drug choice, the mortality rate for immunocompromised patients approaches that of immuno-competent
patients.10 However, mortality can vary widely and is noted
to be as high as 80% in cases, particularly in patients with
underlying disease where lack of prompt recognition and
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treatment initiation exist, and in nosocomial or large outbreaks.
Decreasing mortality trends have been noted recently due
to increased awareness and consideration of the disease as a
possible infectious etiology.
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Acquired Hemophilia A: A Case Report
Gunjan Shah, MD, Ajay Kandra, MD, Douglass A. Drelich, MD
Case Report

A 61-year-old African American male, with a past medical
history of asthma and benign prostatic hypertrophy, presented
from an outside hospital with complaints of hematuria and
hematemesis. He had initially noted increased bruising two
months prior to admission. He also had symptoms suggestive of
a non-traumatic thigh hematoma the month prior. He developed
hematuria one month prior to admission and underwent an
outpatient cystoscopy one week prior to admission which
was non-diagnostic. Cystoscopy was repeated on the day of
admission localizing the hemorrhage to his right kidney with a
biopsy specimen suggesting a low-grade papillary neoplasm. The
patient subsequently developed hemetemesis. Emergent esophagogastroduodenoscopy (EGD) at the outside hospital revealed
a Mallory-Weiss tear. Epinephrine was injected with initial
hemostasis. EGD was repeated after transfer due to recurrent
hematamesis and clips were placed to control the hemorrhage.
The patient experienced continued hematuria requiring repeat
cystoscopy with laser ablation, as well as biopsy of the right ureter
and right mid-pole infundibulum. However, multiple repeated
biopsies failed to confirm the presence of malignancy.
On admission, he was afebrile, with a heart rate of 94 bpm, blood
pressure of 142/88mm Hg, and oxygen saturation of 100% on
room air. His physical exam was within normal limits .His initial
hemoglobin was 7.6 g/dL, white blood cell count of 9,700 cells
per cubic millimeter (cmm), and platelet count 138,000 cells
per cubic millimeter. Coagulation studies revealed an elevated
activated partial thromboplastin time (aPTT) of 76.5 seconds.
An aPTT mixing study was performed with the aPPT correcting
to 34.9 seconds (normal 23.6-35 seconds). Incubation was not
performed. Additional laboratory evaluation demonstrated
factor VIII <0.01 U/ml (normal 0.52-1.43 U/ml) and a factor
VIII antibody was detected with a measured titer of 33.3
Bethesda Units (BU). Von Willebrand antigen and activity levels
were in the normal ranges.
Given the undetectable Factor VIII level, lack of prior history
of a bleeding diathesis, and the presence of an inhibitor with a
high titer level, a diagnosis of Acquired Hemophilia A (AHA)
was made.
The initial management strategy was to control the acute
bleeding and eradicate the inhibitor. Hemostasis was initially
obtained with recombinant Factor VIIa (rFVIIa) at 90mcg/
kg every 3-4 hours episodically for major bleeding for 6-12
hours and prior to planned invasive procedures. However
due to a decrease in clinical response during the admission, it
was switched to activated Prothrombin Complex Concentrate
(aPCC), specifically factor eight inhibitor bypass activity
(FEIBA).

Immunosuppression was initiated with 60 mg of prednisone
daily.3,30,31 He continued to experience severe hematuria requiring
continuous bladder irrigation and multiple cystoscopies for
clot evacuation and laser fulguration. Five days after initiation
of prednisone, the patient failed to show significant clinical
improvement, which warranted replacement with another type of
immunosuppressive therapy. Pulsed high-dose dexamethasone
40 mg (Dex)45-49 and Rituximab35-40 were administered for a
period of four days. However, the patient had a grade 4 reaction
to the Rituximab consistent with anaphylaxis requiring cessation
of the treatment. He then received intravenous immunoglobulin
(IVIG) for two days25-27 without any clinical response.
Given his inadequate response to standard and high dose
steroids and IVIG, and a factor VIII level of 2% with an inhibitor
titer of 40 BU, oral cyclosporine was initiated on hospital day 22
and titrated to maintain a therapeutic goal of 200-400ng/ml.41-44
His hematuria gradually improved, and he required no further
transfusions.
Over the course of his 36-day hospitalization he received a total
of 22 units of pRBC, 9 units of FFP, 34 doses of rFVIIa, and 6
doses of FEIBA. He was discharged on a therapeutic dose of oral
cyclosporine with a Factor VIII level of 4% and an inhibitor titer
of 57.1 BU at the time of discharge (Graph 1).
He was evaluated weekly following discharge during which he
did not have any major hemorrhage. His cyclosporine dose was
titrated based on trough levels. He continued pulsed, high-dose
dexamethasone for 4 consecutive days every 28 days. His Factor
VIII level demonstrated gradual improvement during this period
and inhibitor levels gradually decreased. Following the fourth
cycle of high-dose dexamethasone, his Factor VIII level rose to
29% and his inhibitor level became undetectable. Dexamethasone
was discontinued following the fourth cycle after obtaining an
undetectable inhibitor level. Cyclosporine weaning was initiated
following two consecutive factor levels greater than 80%.

Discussion

Acquired Hemophilia A (AHA) is a rare condition in which
autoantibodies, usually of the IgG class, are produced against
Factor VIII. This results in low plasma Factor VIII levels. Its
incidence ranges from 0.2-4 cases/million/year according
to various reports.1,2,3,4,5 However, given the complexity of
diagnosis, the condition may be under diagnosed.11,12,15 The
incidence increases with age with a peak incidence in the 7th and
8th decade of life. There is a small peak in the 3rd decade likely
corresponding to postpartum inhibitors.3 The mortality rate is
high, ranging from 8%-22%. This is related to severe hemorrhage
that can occur in 85%-90% of the patients.3,4 Approximately half
of the cases are associated with underlying conditions including
pregnancy, autoimmune disorders, malignancy, medications,
dermatologic conditions, inflammatory bowel disease, and
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infections such as hepatitis B and C. The other half occur
without evidence of a coexisting disorder (idiopathic).3,6,7,8,9,10
This condition commonly presents with mucosal bleeding
(including epistaxis, gastrointestinal, and genitourinary),
ecchymosis, and soft tissue hemorrhage including retroperitoneal
bleeding. In contrast to congenital Hemophilia A, hemarthrosis
is rare.3,4
The diagnosis is confirmed by detection of a prolonged aPTT
which does not correct by 1:1 mixing with normal plasma (aPTT
mixing study). Occasionally, there is immediate correction
but after incubation for 2 hours at 37°C there is reversal of
the correction. Factor VIII levels are markedly reduced, and
anti-FVIII antibodies are detectable.
The primary goals of treatment for AHA are to control acute
bleeding and to suppress the autoantibody. Antibody eradication
often requires treatment of the instigating condition when present.
AHA can represent a transfusion emergency requiring intensive
transfusion support.13 In patients with high titer inhibitors (>5
BU), bypassing agents, such as FEIBA and rVIIa, are the mainstay
of therapy for acute hemorrhage.4-21 The recommended dose of
FEIBA, ranges between 50–100 U/kg administered every 6–12
hours, not to exceed a single dose of 100 U/kg or a daily dose of
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Inhibitor Titer (BU)

200 U/kg.3,14,15,16 In one study, FEIBA controlled hemorrhage in
86% of patients.14 The recommended dose of rVIIa ranges from
90 to 120 mcg/kg every 2-3 hours.17-21 A pooled analysis of data
of 139 patients from different sources reported an efficacy rate
of 88%.17 Venous thromboembolic disease (VTE) is an adverse
event associated with both of these agents.

Factor VIII in large doses should be considered in patients
known to have low-titer inhibitors (<5 BU). Porcine Factor
VIII from pooled plasma, while not currently available in
the US, has been used historically to increase plasma factor
VIII levels, and it takes advantage of the minimal antigenic
cross reactivity with human Factor VIII inhibitors.22,23,24 A
recombinant porcine factor VIII, B-domain deleted (OBI-1)
has recently been tested in a clinical trial in the US (50).
A number of immunosuppressive therapies have been used
to control inhibitors. However, current treatment is based on
small, uncontrolled, single-center cohorts and meta-analysis.
Corticosteroids and cytotoxic drugs, used either alone or in
combination, have been regarded as the mainstay of therapy.
An alternate modality of inhibitor suppression is IVIG;
however, this has generally been less effective.11,25,26,27 Removal
of the inhibitor via an immunoadsorption process has been
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attempted.3,28,29 But this process requires central venous access,
specialized equipment and training, and close FVIII monitoring.
Oral steroids used alone at 1 mg/kg prednisone equivalents per
day for 3–6 weeks can cause remission in one third to one half
of patients with acquired hemophilia.3,16,30,31 Cyclophosphamide
has been used as initial therapy and in refractory patients with
high-titer inhibitors (>5 BU) leading to higher remission rates
of up to two-thirds versus steroids alone.1,3,11,16,32,33 However,
a 2-year national surveillance report of acquired hemophilia
A by the UK Haemophilia Centre Doctors’ Organization
concluded that there was no difference in inhibitor eradication
or mortality between patients treated with steroids alone or with
a combination of steroids and cytotoxic agents.11
Several reports have demonstrated the effectiveness of
Rituximab in acquired hemophilia A. The general high level of
tolerance of this drug has led to initial use of this treatment.
However, there is currently no data to establish its superiority
over other treatments. The dose typically given is 375 mg/m2
infused weekly for 4 weeks and administered concomitantly
with other immunosuppressive drugs.34-39
Cyclosporine (CsA) has also been used for inhibitor
suppression.40-43 Use of CsA requires monitoring drug levels to
ensure efficacy and prevent toxicity. However, its use is limited
due to availability of other strategies such as cytotoxic drugs and
Rituximab.
We describe a case of AHA with high titer antibody that
experienced clinical deterioration on initial monotherapy with
prednisone. The patient was unable to tolerate Rituximab due
to anaphylaxis and was also refractory to IVIG.
We report a novel strategy of combining Cyclosporine with
pulsed, high dose dexamethasone at a dose of 40mg daily for four
consecutive days every 28 days. Pulsed dose dexamethasone is
an acceptable modality of immunosupression and has been used
for the treatment of Idiopathic Thrombocytopenic Purpura
(ITP), another immune-mediated hematological disorder.44-48
In general it is tolerated well, without producing the long term
effects of steroid toxicity. No randomized trials exist comparing
the efficacy and tolerability of pulse dose dexamethasone with
longer duration steroids. However, we have experienced good
results in our institution for the treatment of ITP, and this has
become our preferred first line therapeutic modality. The patient
tolerated this regimen extremely well and went into complete
remission with undetectable antibody titers after the fourth
cycle of pulse dexamethasone. He is currently in remission and
is being weaned from cyclosporine.
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Management of an Unresponsive Patient with Severe Acidosis
Nnaemeka Anyadike, MD, Christie Crawford, MD
Case Report

urine drug screen, an acetaminophen level, a salicylate level,
a serum ethanol level, and serum and urine osmolalities were
obtained. These laboratories were remarkable for benzodiazapines
in the patient’s urine and a serum osmolality of 394mOsmol/kg,
resulting in an osmolar gap of 89.1mOsmol/kg.

CHF patients commonly experience muscle weakness and
fatigue as two major symptoms. An altered intracellular
handling of ionized calcium has been suggested to play a vital
role in impaired myocardial contraction.3 In isolated myocytes
from patients with end stage heart failure, systolic ionized
calcium levels were markedly decreased, while diastolic levels
were elevated as compared to healthy controls. 4 In addition,
digitalis and beta-blocker medical therapy is frequently used
in CHF patients and is known to increase myocardial ionized
calcium levels.5

At this point, the differential diagnosis included ethylene glycol,
isopropyl alcohol, or methanol toxicity and laboratories for these
toxins were sent. Poison control was contacted and the patient
was started on fomepizole infusion at 15mg/kg. The patient’s
clinical condition continued to deteriorate. Her acidosis and
acute renal failure worsened, necessitating the initiation of
continuous venovenous hemodialysis. The patient remained
unresponsive, and neurology consultation deemed that her
prognosis was extremely poor.

Congestive heart failure (CHF) is a chronic medical condition whose
incidence is rising. The prevalence of CHF is approximately 1% to
3% in Western countries.1 Despite innovations in medical therapy,
CHF is associated with high morbidity and mortality rates.2

The patient’s past medical history was notable for fibromyalgia
and migraine headaches, and her past surgical history included
a tonsillectomy. Her past psychiatric history was significant for
depression and a prior suicide attempt, involving wrist slitting.
The patient had no known drug allergies and her medications
included valium, topamax, oxycontin, percocet and lunesta as
needed. She did not take any over the counter medications or
herbal supplements. The patient consumed alcohol occasionally
and smoked cigarettes, but did not use any illicit drugs. Her
family history was unremarkable.
Upon admission, the patient’s vital signs were notable for a
temperature of 102°F and a heart rate of 140 beats per minute.
Physical exam revealed dry mucous membranes and tachycardia.
On neurologic exam, the patient was found to be unresponsive to
all stimuli, including sternal rub. Neurologic exam was remarkable
for a left pupil that was sluggishly reactive to light, a right pupil
that was midposition and fixed, and the absence of a gag reflex
and corneal reflexes. Routine laboratories were notable for a white
blood cell count of 31B/L, hemoglobin 17.6g/dL, serum sodium
150mmol/L, serum chloride 118mmol/L, bicarbonate 5mmol/L,
creatinine 1.6mg/dL, and an anion gap of 31mmol/dL. Also of
note, an arterial blood gas performed at the time of presentation
showed a pH of 6.76, PCO2 32mmHg, PO2 345mmHg,
bicarbonate 4mmol/L, and an oxygen saturation of 99% on 100%
FIO2. A CAT scan of the head at the time of admission showed
diffuse cerebral edema with no infarct identified.

Hospital Course

This critically ill patient with a severe metabolic acidosis was
admitted to the intensive care unit. She was aggressively hydrated
and started on a bicarbonate infusion for treatment of her acidosis.
She was also given a dose of mannitol to reduce the risk of cerebral
herniation in light of her diffuse cerebral edema. Additionally, she
was started empirically on broad spectrum antibiotics. As there
was a concern for a possible suicide attempt via an overdose, a

On the second day of hospitalization, the patient’s metabolic
disturbances continued to worsen, and she developed lactic
acidosis with rhabdomyolysis. Her ethylene glycol level came
back elevated at 39mg/dL. Since all other avenues of treatment
had been exhausted and patient’s clinical status was continuing
to decline, Thomas Jefferson University Hospital’s hypothermia
protocol was initiated.
After 24 hours, patient was rewarmed and her electrolyte
disturbances and acidosis began to resolve. The patient, however,
remained unresponsive. On the forth day of hospitalization, the
patient’s neurologic status began to improve, as she was able to
open her eyes and move her extremities. At this point, she was
noted to have right sided weakness so a CAT scan of her head
was repeated, which showed a new left occipital lobe infarction
and slightly decreased cerebral edema.
On the sixth day of hospitalization, the patient began following
commands and was extubated. At this point, her mental status was
completely back to baseline and she had no neurologic deficits.
Her renal function remained poor and she was continued on
hemodialysis. The patient was transferred to inpatient psychiatry
on day 10 of her hospitalization. While on the inpatient psychiatry
floor, her renal function improved and dialysis was discontinued.
She was discharged home from inpatient psychiatry after 12 days,
with no residual neurological symptoms.

Discussion

Although not a significant cause of mortality in the US, ethylene
glycol consumption is responsible for dozens of fatal intoxications
annually. It is a major constituent of antifreeze, de-icing solutions,
windshield wiper fluid, solvents, cleaners, and fuels. Typically
consumption is due to suicide attempt but can also be secondary
to ethanol substitution or accidental consumption. Significant
toxicity can be seen with consumption of small amounts, and
toxic levels of 1g/kg are considered lethal. 1,2
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Ethylene glycol is metabolized by alcohol dehydrogenase and
aldehyde dehydrogenase. The parent molecule itself is nontoxic,
but is noted to cause CNS depression. Its metabolites, primarily
glycolate, glyoxylate and oxalate are responsible for the toxic
effects of ethylene glycol. Upon consumption, ethylene glycol is
rapidly absorbed by the stomach and small intestine, achieving
peak concentrations within one to two hours. The half-life of
ethylene glycol ranges from 3 to 9 hours or longer if alcohol
dehydrogenase is inhibited.3

improved survival in the group receiving hypothermic cooling.5
Similar findings were noted in the Hypothermia After Cardiac
Arrest Study Group as well. 6 A study using animal models
elucidated mechanisms by which hypothermia may be
neuroprotective including: decreased excitotoxic neurotransmitters, diminished oxidative stress, suppressed cerebral
edema preserving blood brain barrier, decreased post-ischemic
inflammation, normalized acid-base status in brain, and
restoration of protein synthesis.7

Typically, the progression of symptoms from ethylene glycol
consumption includes initial CNS symptoms, followed
by cardiopulmonary manifestations, and ultimately renal
involvement. The presentation can be largely variable depending
on the amount ingested, the degree of metabolism, and the
presence of ethanol co-ingestion. A wide spectrum of systemic
effects can occur. In addition, in the preterminal stage of the
illness, cerebral herniation and multi-system organ failure are
often present.1,2

At Thomas Jefferson University Hospital, the hypothermia
protocol was adopted for use with patients status post cardiac
arrest. However, given this patient’s neurological presentation,
the protocol was instituted for neuroprotective purposes. In
addition, intoxication due to ethylene glycol was the cause of
her neurological dysfunction and also a contraindication to
the use of hypothermic cooling per the institution’s protocol.
However, in our patient’s case there were several mitigating
circumstances: the threat of herniation, inability to use mannitol
due to her elevated serum osmolality, and her young age that
warranted the use of hypothermic cooling.

Blood work typically reveals a profoundly elevated anion gap
metabolic acidosis with a lactate level insufficient to account for
the degree of acidosis. Also, the patient can have an elevated
plasma osmolar gap. However, no single laboratory study, with
the exception of an elevated serum ethylene glycol level, is
definitively diagnostic for ethylene glycol poisoning. A serum
osmolar gap is present in a variety of intoxications including
ethanol, isopropyl alcohol, and methanol toxicity.1,3
A high clinical suspicion for intoxication and early treatment
are essential for the successful management of a patient with
ethylene glycol ingestion. The core components of managing
ethylene glycol toxicity include maintenance of cardiopulmonary function as well as the use of the alcohol dehydrogenase
antagonist fomepizole, sodium bicarbonate infusion,
hemodialysis, and consultation with medical toxicology and
poison control.1
Generally, the use of intravenous sodium bicarbonate is
recommended for metabolic acidosis with a pH less that 7.3.
Infusions have been shown to increase excretion of active
metabolites, as well as decrease end organ damage. Fomepizole
is an antidote for methanol and ethylene glycol poisoning that
acts as a competitive antagonist of alcohol dehydrogenase.
It has a binding affinity of greater than 8,000 times ethanol
and has efficacy that may obviate the need for hemodialysis.
Hemodialysis rapidly removes toxic metabolites and is mostly
indicated for use in patients with acute renal failure, as renal
function may take days to months to recover.4 The hypothermia
protocol utilized in our patient has no evidence-based support
for treatment of ethylene glycol associated cerebral edema. Its
established use has been in patients who are status post cardiac
arrest to preserve neurological function in the setting of cerebral
hypoperfusion. Bernard et al. conducted a study of 77 subjects
randomized to normothermic and hypothermic treatment after
ventricular fibrillation arrest and resuscitation with a significant
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Images in Clinical Medicine: Erythema Migrans
Jack Stewart MD, Luis Taboada MD, Joanne Kim MD
Case Report

Patient is a 30 year old male, with no significant past medical
history, who was attending an outdoor party in a wooded area
of New Jersey two weeks prior to this hospital admission. Three
days following the party, patient noted several papules on his
lateral left calf with surrounding erythema. The following day
he went to the emergency department and was diagnosed with
bacterial cellulitis (Figure 1).

given his clinical history. Patient was started on broad spectrum
antibiotics and doxycycline. The following day, rash was revaluated
(Figure 3) and he was diagnosed with erythema migrans.

Figure 3. Left lateral calf rash on day 2 of admission.
Patient’s condition improved quickly and he was discharged
home on a 28 day course of doxycycline.

Discussion
Figure 1. Rash located on lateral left calf on initial presentation.
Patient was discharged home from the emergency department
with a 14 day course of Bactrim DS. However two days following
his emergency room visit the rash had progressed despite
adherence to the antibiotics prescribed. At that time, patient
returned to the emergency department (Figure 2).

Erythema migrans occurs in approximately 80 percent of
patients and generally manifests within one month following
the tick bite. Although the lesions of erythema migrans are
typically described as a “bull’s eye” and central clearing is
considered classic, it often requires considerable expansion of
the lesion and, in some instances, is not present early on in the
illness. Thus in the first days eythema migrans lesions may be
uniformly red.
In light of this information, it is important to consider a wide
differential, especially in the early stages of the disease. In
addition to Lyme disease, other tick borne illness producing
rash such as Rocky Mountain spotted fever, ehrlichiosis, and
tularemia should be considered.

Figure 2. Left lateral calf rash following two days of Bactrim.
The patient was presumed to have either a refractory cellulits
secondary to skin flora or infection with Borrelia burgdorferi

Despite the availability of an effective vaccine, measles (rubeola)
can present as a blanching erythematous maculopapular rash
beginning in the head and neck area and spreading down to
the trunk and extremities. The rash of infectious mononucleosis
is usually over the trunk but can involve the extremities,
including the hands and feet. Acute retroviral syndrome
occurring 2-4 weeks after primary HIV infection can manifest
as a transient, maculopapular, nonpruritic rash that is usually
truncal or facial in location. Approximately 20 percent of cases
of erythema infectiosium occur in adults and can manifest with
a rash described as first macular and then lacy and reticulated,
spreading initially from the limbs to the trunk and buttocks.
Additionally, mycoplasma infection may be accompanied by

19

skin findings ranging from a mild erythematous maculopapular
or vesicular rash to Stevens-Johnson syndrome.

with more severe cardiac involvement, intravenous ceftriaxone
or cefotaxime is recommended.

Treatment options for lyme disease differ depending on the
clinical scenario. For erythema migrans, amoxicillin is as
effective as doxycycline and is preferred for children and
pregnant or lactating women. Oral antibiotic treatment for
14-21 days shortens the duration of the rash and generally
prevents development of late sequelae. Cefuroxime is also
effective, but significantly more expensive. For patients with
facial nerve palsy alone, oral doxycycline or amoxicillin may
be effective. Patients with other neurologic involvement, such
as meningitis, cranial nerve palsies, radiculopathy or cognitive
deficits, should be treated with IV ceftriaxone or cefotaxime
for 14-28 days.

Oral therapy with doxycycline or amoxicillin for 28 days is
usually effective for treatment of Lyme arthritis. Patients
who have not responded to oral treatment may respond to a
second course of oral therapy or to intravenous therapy with
ceftriaxone or cefotaxime.

In patients with minor cardiac conduction disease associated
with Lyme disease treatment with oral doxycycline or
amoxicillin should be sufficient; however, for those patients

“Arc de Triumpe” Photograph by Cecilia Kelly, MD
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A Case of Acute Spontaneous Tumor Lysis Syndrome and
New Diagnosis of Burkitt’s Lymphoma
Ryan D. Gentzler, MD
Introduction

Tumor lysis syndrome is a well-described phenomenon
characterized by elevated serum levels of calcium, uric acid,
potassium, phosphate, and lactate dehydrogenase due to lysis of
tumor cells and release of intracellular contents. Acute kidney
injury may occur as the result of precipitation of intrarenal
calcium phosphate salts related to the rapid destruction of
a large number of tumor cells. 1 Tumor lysis syndrome most
often occurs during induction chemotherapy for aggressive
leukemia or lymphoma, particularly those with large tumor
burden.1 While tumor lysis syndrome is more commonly seen
in patients receiving chemotherapy, it can occur spontaneously
and has been described in aggressive malignancies, such as
AML,2 Burkitt’s lymphoma in children1 and adults, 3 and in
solid malignancies, such as breast cancer.4 This case describes a
patient who presented with a neck mass and spontaneous tumor
lysis syndrome.

Case Presentation

A 76-year-old male with a past medical history of hypertension,
hyperlipidemia, and coronary artery disease presented with
epistaxis and a neck mass that was first noted four weeks prior to
presentation. In addition, the patient noticed gingival bleeding
when brushing his teeth, malaise, decreased appetite, and night
sweats, all of which developed during the previous week. His
exam was significant for an ulcer with scab on his left buccal
mucosa, a 6-cm left neck mass that was firm and non-tender,
and several areas of ecchymosis on his arms bilaterally. There
was no axillary or inguinal lymphadenopathy. The remainder of
the exam was unremarkable.
A neck ultrasound prior to admission showed multiple left
cervical cystic and solid masses consistent with necrotic lymph
nodes. The patient also had an enlarged right cervical lymph
node. He was admitted with a diagnosis of left neck mass
suspicious for malignancy and acute kidney injury.
On admission, laboratory data showed white blood cell count
of 5,300/mL, a platelet count of 3,000/mL, hemoglobin 12.5 g/
dL, and a mean corpuscular volume of 94 fL. The white cell
count differential included 23% neutrophils, 10% bands, 28%
lymphocytes, 13% atypical lymphocytes, 2% monocytes, 1%
metamyelocytes, 5% myelocytes, 2% promyelocytes, 16%
blasts, and 3.4/100 WBC nucleated red cells. Other significant
laboratory data included potassium of 4.5 mmol/L, blood urea
nitrogen (BUN) of 46 mg/dL, creatinine of 1.6 mg/dL, total
bilirubin of 2.1 mg/dL, direct bilirubin of 0.7 mg/dL, uric acid
of 17.4 mg/dL, and lactate dehydrogenase (LDH) of 4795 IU/L.
The patient’s elevated LDH, uric acid, and creatinine raised
suspicion of tumor lysis syndrome, so IV fluid hydration and

allopurinol were initiated. A bone marrow biopsy was performed
for diagnosis of suspected lymphoma. The patient’s creatinine,
LDH, and uric acid levels continued to rise, and treatment with
rasburicase was initiated given the concern for renal failure.
In less than 12 hours, the patient’s creatinine increased from
2.6 mg/dL to 3.5 mg/dL and potassium increased from 5.2
mmol/L to 6.1 mmol/L. The patient suffered cardiac arrest
before dialysis could be initiated. Although he was initially
resuscitated, care was withdrawn the same day per the patient’s
and family’s wishes.
The final bone marrow biopsy results, including flow cytometry
and FISH analysis, revealed solid monotonous sheets of large
atypical lympohoid cells with clear cytoplasmic vacuoles, which
accounted for the vast majority of nucleated bone marrow cells.
The cells demonstrated a monoclonal B-cell proliferation with
translocations at 8;22 involving the C-myc gene, consistent
with the diagnosis of Burkitt’s lymphoma. These results were
obtained several days after the patient had expired.

Discussion

Tumor lysis syndrome is a familiar entity to physicians caring
for patients receiving chemotherapy for treatment of leukemias
and lymphomas. This syndrome is most commonly encountered
upon initiation of chemotherapy in a patient for the first time,
but it can occur in any patient with extensive tumor burden,
including patients with solid malignancies. Patients may
exhibit hypercalcemia, hyperkalemia, hyperphosphatemia,
hyperuricemia and acute renal failure. Often prophylactic
intravenous fluid hydration and administration of allopurinol
or rasburicase are initiated prior to giving chemotherapy to
reduce the risk of developing renal failure and fatal arrhythmias
secondary to hyperkalemia. In addition, frequent monitoring of
serum potassium levels allows for treatment of hyperkalemia,
should it develop.
In the case presented above, tumor lysis syndrome was not
an anticipated event since chemotherapy was not being given
at the time of its development. Moreover, the patient had not
been diagnosed with a malignancy at the time of development
of the syndrome. Although it has been described before in the
literature, this uncommon presentation of spontaneous tumor
lysis syndrome could be easily missed. Knowing that spontaneous
tumor lysis syndrome can occur, it seems reasonable to obtain
serum lactate dehydrogenase and serum uric acid levels in
patients suspected of having a new diagnosis of a hematologic
malignancy even before the formal diagnosis is made. It is
important to initiate standard treatment of IV fluid hydration
and allopurinol or rasburicase as early as possible when tumor
lysis syndrome is suspected.
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A Case of Babesiosis Complicated by Hepatic and Renal Failure
Steven Krawitz MS IV, Nilay Kavathia MD, Pratik Choksy MBBS
Case Report

A 67-year-old male with a past medical history of chronic kidney
insufficiency, splenectomy, and recurrent babesiosis infection
was transferred to with jaundice and abdominal pain.
The patient initially presented to an outside hospital (OSH) with
generalized weakness, chills, and gastrointestinal symptoms and
was found to have Babesia on peripheral blood smears. The
patient received seven days of azithromycin and atovaquone,
followed by three days of clindamycin and quinine sulfate.
The patient was discharged home with improved symptoms
and a negative peripheral blood smear. Less than 24 hours
later he returned to the OSH with worsening myalgias and
abdominal pain. Physical exam was significant for jaundice
and hepatomegaly. Laboratory data revealed anemia, elevated
creatinine, bilirubin of 30 mg/dL, and 1% parasitemia. At this
point the patient was transferred for further management.
Patient’s past medical history was significant for chronic renal
insufficiency, congestive heart failure, type 2 diabetes mellitus,
coronary artery disease, and hypertension. Previous surgical
procedures included splenectomy after a motor vehicle accident,
below the knee amputation (BKA) of the right leg, and cholecystectomy. Patient denied alcohol or substance abuse, and quit
smoking tobacco approximately 10 years ago. He is a retired
carpenter and denied any recent history of travel. Medications
on admission included digoxin, clopidogrel, isosorbide
mononitrate, carvedilol, sucralfate, esomeprazole, metoclopramide, amlodipine, octreotide, and insulin lispro.
On examination, patient looked fatigued, but in no acute distress.
He was afebrile and had stable vital signs. Physical exam
was significant for scleral icterus, ventral hernia and diffuse
blanching, maculopapular rash on patient’s hands and soles.
Patient was admitted and started on treatment with clindamycin
and quinine. The patient’s blood smear showed Babesia
species with a 1.7% parasitemia (figure 1). During the hospital
stay, patient had an acute mental status change with asterixis.
Laboratory data obtained at that time revealed elevated INR,
bilirubin, and ammonia levels. Given the clinical findings,
patient was started on lactulose for possible hepatic encephalopathy. Hepatitis serology was found to be negative. Dialysis
was initiated in the setting of acute renal failure. Patient’s
clinical status continued to worsen, so red blood cell exchange
transfusion was initiated in an attempt to reduce the parasite load
and help clear the infection. Despite the exchange transfusion
and continued antibiotic treatment, the patient continued to have
hemolysis, paracitemia, renal failure, and hepatic failure. At that
point hospice discussion was initiated and patient was eventually
transferred to hospice home care.

Discussion

Babesiosis is a tick born protozoan infection of red blood cells
from the genus Babesia. The first human case was reported
in 19571. The four Babesia species that most commonly infect
humans in decreasing order of incidence are B. microti, B.
duncani, B. divergens, and B. venatorum. Babesiosis is a zoonotic
infection requiring both an animal reservoir (usually mice) and
a vector, which in humans is the Ixodid tick. The protozoan
is transmitted through the saliva of a tick when it bites. Other
possible modes of infection include perinatal transmission and
blood transfusion.
The endemic areas for babesiosis show significant overlap with
Lyme disease and ehrlichiosis2. The disease is most commonly
seen in the northeast of the United States, and the most common
cause of babesiosis in America is the B. microti species. While
the majority of the early cases were seen in coastal areas near
Massachsetts, babesiosis is now diagnosed with regularity in
Rhode Island, Connecticut, and even New York and New Jersey3.
Many cases have now been reported in other states stretching as
far west as California and even Europe has confirmed cases of
B. microti babesiosis.
The severity of babesiosis infection depends on the strain of
parasite as well as host factors such as immune system status or
asplenia. Clinically, patients infected with B.Microti typically fall
into one of three categories of disease expression: asymptomatic,
flu-like, and severe infection. Given the relatively high seroprevalence, many infected individuals are asymptomatic and unaware
they carry the parasite4. One study estimates the prevalence
of asymptomatic infection at about one third of infected
individuals5. However, most infected individuals fall into the
second category, mild to moderate flu-like illness. Similar to
Lyme disease, up to two thirds of these symptomatic patients
cannot recall getting bit by a tick, making diagnosis potentially
difficult6. Patients typically present with malaise and fatigue and
develop intermittent fevers with one of the following in order of
prevalence: chills, sweats, headaches, anorexia, cough, nausea.
Patients with severe disease more often present with malaise,
arthralgia, myalgia, and shortness of breath often combined with
thrombocytopenia and abnormal liver function7. Severe infection
carries with it the potential of numerous serious complications
including DIC, congestive heart failure, acute respiratory failure,
liver and renal failure, and splenic rupture.
Diagnosis of babesiosis infection is typically made by
microscopic examination and identification of the typical
appearance of organisms on Geimsa stained thin red blood cell
smears. Polymerase chain reaction (PCR) amplification, although
more expensive, is more sensitive than microscopic identification and can be completed within one day. For diagnostic
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Figure 1. RBC peripheral smear showing typical babesiosis organisms in the patient’s blood.
confirmation or when both microscopy and PCR are negative,
serologic diagnosis can also be made. The standard treatments
for babesiosis are the antibiotic regimens of clindmycin and
quinine, or atovaquone and azithromycin, both administered for
7 to 10 days. Infections with a high parasitemia load or those
that are persistent or relapsing might benefit from red blood cell
transfusion to lower the parasite level in the blood. However,
even with appropriate treatment, babesiosis can be fatal in
certain patient populations.
Although most cases of babesiosis in the United States are
mild to moderate or even asymptomatic, some cases are severe
and may be fatal. It is important to be wary of the potential
devastation the disease can have as well as who is more likely
to manifest severe disease. The risk factors for severe disease
include age older than 50, asplenia, coinfection with HIV or
Borrelia burgdorferi, and an immunocompromised state. The
case above demonstrates severe and resistant infection in the
setting of multiple risk factors, namely increased age and
asplenia. Though the patient was on appropriate antibiotic
treatment and received multiple red blood cell transfusions, he
still suffered from complications of the disease and was unable
to clear the infection.
This case demonstrates that babesiosis is a potentially severe and
fatal disease. It is important to recall the risk factors for disease
severity, especially in certain at-risk populations. In treating such
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populations, potential end of life issues should be considered, as
mortality and complications from the disease are significant.
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A 19 Year-Old Man With Chest Pain
Sam Barasch, MS IV, Sugeet Jagpal, MD
Case Report

A 19-year-old man with no past medical history presented to
the ER with a sore throat, cough, and pleuritic chest pain. The
patient had been well until 1 month before admission, when
he developed a sore throat and felt ill. He presented to the
emergency department twice for these symptoms. On the first
visit, the patient had a positive rapid strep test. He was diagnosed
with strep throat and treated with penicillin IM. However, his
sore throat persisted. Five days before admission, the patient
developed a non-productive cough. One day prior to admission
he developed severe right sided chest pain that was throbbing,
pleuritic, and radiated to his right shoulder. The pain, which
was initially relieved by sitting forward and with Ibuprofen,
continued to worsen, prompting the patient’s mother to bring
him back to be re-evaluated.
Upon presentation, the patient denied shortness of breath, fevers,
or chills. He had no personal history of prenatal or childhood
disease, and denied family history of early heart disease, lung
disease, cancer or bleeding disorders. He denied tobacco,
alcohol, or illicit drug use. He reported being heterosexual with
4-5 lifetime sexual partners, and one new partner in the prior
two months.
On examination, the patient was a well nourished, well
developed, young African American man in moderate distress.
The blood pressure was 117/57, heart rate 66, respiratory
rate 16, oxygen saturation 98% on 2 L nasal cannula and
temperature 37.5ºC. The physical exam was remarkable only
for slight pharyngeal erythema and enlarged, non-purulent
tonsils. His heart was without murmurs, rubs, or gallops. His
lungs were clear to auscultation bilaterally. Initial labwork
was unremarkable, with a normal white blood cell count. A
chest radiograph revealed findings in the right lower lobe
concerning for subsegmental atelectasis versus consolidation.
Electrocardiogram demonstrated an incomplete right bundle
branch block. A thoracic CT demonstrated a large right lower
lobe pulmonary embolism with an associated area of pulmonary
infarction.
Given the finding of the patient’s pulmonary embolism, our
top three differential diagnoses were a primary underlying
hypercoagulable state, an infection predisposing the patient to a
hypercoaguable state, or an underlying malignancy. The patient
was admitted to the hospital, blood work was drawn, and he
was started on Warfarin with an Enoxaparin bridge. During his
work up, the patient was found to have elevated antistreptolysin
O titers, consistent with a prior streptococcus infection. Blood
cultures were negative. In addition, HIV, HSV, gonorrhea,
chlamydia, group A strep, and H1N1 PCR were all negative.
CT of the abdomen and pelvis and testicular ultrasound were

normal, without any signs of malignancy. A rheumatologic
workup, including an anti-nuclear antibody and anti-neutrophil
cytoplasmic antibody were negative. A hypercoagulable work up
was sent prior to initiation of anticoagulation therapy. Protein
C, protein S, factor V leiden, antithrombin III, and anticardiolipin antibodies were normal. Eventually, after the patient
had been discharged, his lupus anticoagulant levels returned as
abnormally elevated. The patient was diagnosed with primary
antiphospholipid syndrome by his primary care doctor and was
informed he would require lifelong anticoagulation.

Discussion

Primary antiphospholipid syndrome is an auto-immune disease
typically discovered when a patient has vascular thromboses or
pregnancy complications in the presence of elevated anticardiolipin antibodies or lupus anticoagulant antibodies. Primary
antiphospholipid syndrome can be diagnosed in the absence of
broader auto-reactive antibody production, i.e. lupus. Detection
of the auto-immune antibodies must be found on two separate
occasions more than six weeks apart.
Of the laboratory criteria, anticardiolipin antibodies are more
sensitive while the lupus anticoagulant antibodies are more
specific. Lupus anticoagulant antibodies were originally found in
lupus patients who had a prolonged activated partial thromboplastin time (aPTT). While patients with the lupus anticoagulant
had prolonged in vitro coagulation studies, in vivo they were
hyper-coaguable. Thus, these patients had high PTT or INR
on blood work, in combination with a paradoxical tendency to
clot in their body. This paradox is due to the fact that, in vitro,
the lupus anticoagulant antibody binds to critical phopholipids
and prevents them from activating factor X and prothrombin.
In vivo, however, the antiphospholipid antibody binds to a
multitude of targets that result in a hyper-coaguable state.
The lupus anticoagulant antibody has many significant targets
within the body. The most clinically important in vivo target
is β 2-glycoprotien. 2 Many patients have circulating lupus
anticoagulant antibodies that target phospholipids only, and
do not have clinically significant thrombosis. However, when
the antibodies target both phospholipids and β2-glycoprotien
I, the patients become much more likely to have a thrombus
that causes symptoms. Antiphospholipid antibodies also
promote coagulation by enhancing activation and aggregation
of platelets, activation and expression of adhesion molecules on
endothelium, and activation of the coagulation cascade.
Infection can be an inciting factor for a thrombotic event in
a patient with a circulating, but clinically silent, antiphospholipid antibody. Many different pathogens are cited, including
HIV, HCV, VZV, H influenza, Streptococcus species, and
Staphylococcus aureus. Common systems infected prior to
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thrombosis include skin, pulmonary, urinary, and upper
respiratory tract. 4 Some investigators propose a “two hit”
hypothesis in which patients with underlying antiphospholipid
antibodies receive a second hit when a pathogenic epitope is a
molecular mimic of β2-glycoprotein I or when an inflammatory
cascade is activated by toll-like receptors on phagocytes of the
innate immune system. It is possible this happened to our
patient: his previously silent circulating antibodies were activated
by an upper respiratory streptococcus infection, causing an
inflammatory cascade that resulted in a thrombotic event.

Our patient did not have catastrophic antiphospholipid
syndrome, and is currently doing well on oral anticoagulation.

Treatment for patients with primary antiphospholipid syndrome
centers on anticoagulation therapy. An INR of 2-3 (maintained
by oral warfarin) has been shown to reduce the probability of
recurrent thrombosis. In catastrophic cases where life threatening
thromboses affect multiple organs and cause microvascular
disease, treatment includes high dose steroids, intravenous
immunoglobulin, cyclophosphamide, or plasmapharesis.
Treatment in a hemodynamically compromised patient with
pulmonary embolism can also include embolectomy. For
prevention of late term pregnancy loss related to primary
anti-phospholipid syndrome, low dose aspirin and subcutaneous
prophylactic heparin have been shown to prevent complications.
For patients refractory to anti-coagulation, long term immunomodulating agents should be added.

3) I nfection can prompt a circulating but clinically silent
antiphospholipid antibody to cause a thrombotic event.
Exact mechanism of this is unknown.
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Take home points:

1) P
 rimary antiphospholipid syndrome is vascular thromboses
or pregnancy complications and anticardiolipin antibodies
or lupus anticoagulant antibodies.
2) A
 nticardiolipin antibodies are more sensitive while lupus
anticoagulant is more specific for diagnosing antiphospholipid syndrome.
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A 67 Year-Old Man with Fatigue
Sam Barasch, MS IV, Ajay Wagh, MD
Case Report

A 67 year-old male with a past medical history of hypertension
and insulin-dependent type II diabetes complicated by
neuropathy, retinopathy, and chronic kidney disease presented
to the hospital with a complaint of fatigue. The patient noted
generalized weakness that had begun the morning of admission
after two days of malaise and subjective fever. This weakness
prevented him from being able to rise from a sitting position,
resulting in a fall off the couch. He denied injury from this fall
along with shortness of breath or chest pain, however, he did
admit to two episodes of vomiting the day prior to admission.
The patient was taking the following medications: furosemide,
aspirin, isosorbide mononitrate, lipitor, levothyroxine,
candesartan, metoprolol, clopidogrel, doxazosin, calcitriol
and Insulin 70/30. Medical history included, hyperlipidemia,
hypothyroidism, benign prostatic hypertrophy, stable angina,
and peripheral vascular disease along with the conditions
listed above. Past surgical history included 2 stents in the LAD
coronary artery, vitrectomy, and transurethral resection of the
prostate (TURP). Additionally, the patient noted that he lived
alone after having retired from teaching and denied any drugs,
smoking or alcohol.
On physical exam, the patient was febrile at 102.2°F, heart rate
was 99, respiratory rate was 17, and blood pressure was elevated
at 183/56 mmHg. Generally, the patient was dehydrated
and appeared to be somnolent but responsive to questions.
Neurological exam was remarkable for generalized bilateral
upper and lower extremity weakness and asterixis with no
focal neurological deficits. His cranial nerves were intact. Skin
exam was significant for a warm, erythematous, blanching,
non-pruritic rash on the left anterior tibial surface, as well as an
eschar on the 2nd toe of the left foot. The rest of physical exam
was within normal limits.
An arterial blood gas was performed due to his overall lethargic
state and demonstrated a pH of 7.34, PCO2 34, PO2 66 and
oxygen saturation of 91% on room air. His electrolytes were Na
134, K 5.3, Cl 106, HCO3 19, significant for a non-anion gap
metabolic acidosis with a compensatory respiratory alkalosis.
Glucose was elevated at 412mg/dl. Additional laboratory values
revealed a BUN of 79 and creatinine of 3.1 (previous baseline
of 2.3). Urine studies showed protein >300 mg/dl, urine pH of
5.5, urine glucose 500, and rare hyaline casts. Urine electrolytes
results included Na 49, K 30.2, Cl 54, and Cr of 98.7. Lactate was
within normal limits.
The patient was treated acutely for dehydration and
hyperglycemia with intravenous fluids and insulin. He was
started on broad spectrum antibiotics for suspected cellulitis
and osteomyelitis of the 2nd left toe. The combined results of
the urine anion gap of + 25.2, the serum anion gap of 9, and

hyperkalemia led us to a preliminary diagnosis of renal tubular
acidosis type IV. Finally, the renin level returned low at 1.4 ng/
mL/hr (normal 1.9-3.7) indicating a low renin – low aldosterone
as an underlying cause of the metabolic acidosis.

Discussion

Type 4 Renal Tubular Acidosis is characterized by a low
renin - low aldosterone state and non anion-gap metabolic
acidosis. Low aldosterone levels impair the normal functioning
of the Na-K-2Cl cotransporter in the distal nephron. This
deficiency results in decreased reabsorption of Na+ in the
distal nephron and decreased excretion of K+ and H+. Thus,
RTA IV is characterized by salt wasting, hyperkalemia and
acidosis.
RTA IV is caused by a decrease in ammonia recycling in medullary
segments of the nephron and the subsequent increased gradient
for alpha-intercalated cells of the collecting duct to pump
protons against. In order to understand how ammonia recycling
is affected in this condition we will examine the nephron from
proximal to distal and discuss how hyperkalemia and acidosis
derange normal physiology.
There are two mechanisms which are believed to be involved
with the dysfunction of ammonia recycling. In the proximal
convoluted tubule the presence of hyperkalemia creates an
extracellular acidosis and intracellular alkalosis. In the loop of
henle, there is competition between NH4+ and K+ for transport
in the thick ascending loop by the Na+/K+/2Cl- transporter.
In the proximal convoluted tubule, hyperkalemia leads to diffusion
of K+ across all cell membranes. In order to maintain electrical
neutrality, H+ diffuses out of the cell into the extracellular
space. This leads to an extracellular acidosis and an intracellular
alkalosis. The intracellular alkalosis inhibits the de-amination
of glutamine and the subsequent exchange of NH4+ with Na+
in the renal proximal collective tubule (PCT). The deficit of
ammonium produced in the PCT makes less ammonia available
in the ammonia recycling system of the renal medulla.1
In the loop of henle, hyperkalemia is believed to contribute to
the acidosis by limiting the amount of ammonia/ammonium
reabsorbed. Renal medullary ammonia recycling is reduced
through hyperkalemia affecting the Na-K-2Cl cotransporter
in the thick ascending limb. This cotransporter can take one
ion of K+ or NH4+ across the luminal membrane of the thick
ascending limb along with a Na ion and two Cl- ions. NH4+
and K+ directly compete for reabsorption. Under physiological
conditions, NH4+ ions are transported intracellularly, lose their
H+, and NH3 diffuses freely into the medullary interstitium
of the kidney while return to the tubule is prevented by a
membrane that is impermeable to NH3. In the absence of
pathology, the high ammonia concentration in the renal medulla
allows diffusion of NH3 down its concentration gradient into
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the medullary collecting duct or the proximal tubule. Once in
the medullary collecting duct, NH3 can accept a donated H+
ion, becomes ammonium, thereby facilitating the excretion of
an acid load.
Under conditions of RTA IV, there is a lesser amount of
ammonium available for renal medullary recycling, as less
is generated in the proximal convoluted tubule, and this
mechanism for excreting acid is further hampered by the
high potassium in the tubule competing for and displacing
ammonium from the loop cotransporter.2
Therefore, both mechanisms of RTA type 4 work together to
inhibit the excretion of NH3 into the collecting duct of the
kidney and subsequently inhibit the excretion of NH4+ and an
acid load.
Under normal conditions, both mechanisms of hampering renal
medullary ammonia recycling can be repaired by aldosterone,
which promotes the re-absorption of Na and the wasting of K.
However, the hallmark of RTA IV is a low renin/low aldosterone
state. In this situation, it is not possible for normal physiological
mechanisms to break the hyperkalemic acidosis of RTA IV.

Treatment of RTA IV

Treatment of RTA type IV focuses on correction of hyperkalemia,
optimizing renal function, and addressing the physiological
root of the disorder.
Correction of hyperkalemia begins with withholding medications
that can cause or exacerbate hyperkalemia. Potassium-sparing
diuretics, ACE-Inhibitors and ARB medications are common
causes. This is especially important because renal insufficiency in
combination with ACEI/ARB medications can have synergistic
hyperkalemic effects.3

Additionally, if the patient suffers from renal insufficiency
he must be treated to optimize renal function. This includes
omission of medications that aggravate interstitial nephritis
such as NSAIDS, cyclosporine, or tacrolimus.4 Also, adjusting
for pre-renal insufficiency by treating volume status and
maximizing renal perfusion is critical in the process of increasing
potassium excretion. Improving renal function will increase
potassium excretion. For long term management of RTA IV, in
cases of renal insufficiency, dietary sources of potassium must
be limited.
Adrenal insufficiency is suspected in a low renin-low aldosterone
state. It is more common in cases of autoimmune disease and HIV
infection.4 If clinical suspicion is high for adrenal insufficiency,
mineralcorticoids should be given. Fludrocortisone is an effective
exogenous mineralocorticoid replacement.5 However, mineralocorticoid replacement is contraindicated in hypertensive or
edematous patients. Instead, in these patients, hyperkalemia can
be managed with a loop or a thiazide diuretic.
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A 54 Year-Old Male with Cholangiocarcinoma and
Biliary Sepsis
Leela Nayak, MD, Bhalaghuru Chokkalingam Mani, MD
Case Report

A 54 year-old male with a past medical history of cholangiocarcinoma and portal vein thrombosis was admitted to an outside
hospital with right-sided abdominal pain, leukocytosis and
hyperbilirubinemia. Prior to admission, he received 3 cycles of
gemcitabine however his tumor had increased in size leading to
development of obstructive jaundice. At the hospital, his pain was
attributed to hepatomegaly and biliary obstruction secondary to
tumor size. He was started on Zosyn for presumed diagnosis
of pneumonia and leukocytosis. He was then transferred to
Thomas Jefferson Hospital for a second opinion regarding his
malignancy.
Upon transfer, patient noted right upper quadrant abdominal
pain that he described as constant and dull. He also reported
fatigue and weight loss over last few months. He denied nausea,
vomiting, diarrhea or any change in his bowel movements.
On arrival, his vital signs were stable. Physical exam was
significant for jaundice, distended abdomen and right upper
quadrant tenderness. He also had significant peripheral edema
up to his groin.
Laboratory studies revealed white blood count (WBC) of
24,500/mL, hemoglobin of 8.5 g/dL, and platelets of 416,000/mL.
His sodium was 128 mmol/L and creatinine was 0.6 g/dL. His
total bilirubin was 21.2 mg/dL and alkaline phosphatase was 320
IU/L. His INR was slightly elevated at 1.31.
The patient underwent endoscopic retrograde pancreatography
(ERCP). He was found to have an occlusive common hepatic
duct stricture secondary to a tumor. A plastic stent was
successfully deployed. Seven days after the initial ERCP, patient
became febrile, tachycardic and complained of worsening right
upper quadrant pain. Repeat ERCP revealed purulent debris in
the stent and a strictured left hepatic duct. Two metal stents were
successfully placed leading to decreased in bilirubin. Within 24
hours, the patient’s blood cultures speciated Stenotrophomonas
maltophilia. He was started on intravenous trimethoprimsulfamethoxazole (TMP-SMX). Once patient’s bacterimia
cleared, he was discharged home with hospice services.

Discussion

In the last twenty years, Stenotrophomonas maltophilia has
been increasingly found as an important cause of infection
in hospitalized patients. This hydrophilic organism has been
known by multiple names. It was originally called Bacterium
bookeri when first isolated in 1943 and considered to be a
member of the genus Pseudomonas. It was then classified as
part of the Xanthomonas genus in 1983 until finally reclassified
as Stenotrophomonas in 1993. Although not considered to be
a highly virulent organism, S. maltophilia can cause serious
infections in both immunosuppressed and immunocompetent patients. It is most commonly found in aquatic or

humid environments including drinking water supplies, soil
and on plants. In health care facilities the organism has been
isolated from medical devices, vacuum blood collection tubes,
disinfectant and sterile water.1
Most infections do occur in severely immunocompromised
patients particularly those with cancer and prolonged
neutropenia. Risk factors for infection with S. maltophilia
include extended hospitalization in critical care units, prolonged
mechanical ventilation, presence of tracheostomy, indwelling
devices such as intravascular catheters and endotracheal tubes,
and exposure to broad-spectrum antibiotics. Most S. maltophilia
bacteremias are related to infected in-dwelling catheters. These
infections are usually easily treated with removal of the infected
catheter and antibiotic therapy. In patients with non-catheter
related S. maltophilia, bacteremia treatment failure rates and
infection associated mortality are high.2 In patients with cancer,
risk factors associated with poor outcome include prolonged
neutropenia, bacteremic pneumonia, shock syndrome,
thrombocytopenia and inappropriate initial antibiotic choice.2
The respiratory tract is the most common site of S. maltophilia
infection however it has been found to be the cause of
skin infections, endocarditis, urinary tract infections and
hepatobiliary infections. There have been five reports in the
literature of biliary sepsis secondary to S. maltophilia. All of
these cases occurred in patients with hepatobiliary malignancy
complicated by biliary tract obstruction. Each of these patients
had undergone biliary tract instrumentation prior to developing
S. maltophilia bacteremia.3,4,5 The organism was recovered from
blood in three cases and from bile in the remaining two cases.
All of the patients were treated with antibiotics, four out of
five patients described made a full recovery, the fifth patient
died. The four patients who survived underwent interventional
procedures in addition to receiving antibiotics.
Choosing appropriate antibiotic therapy for S. maltophilia
infections can be difficult and initiation of inappropriate
antimicrobial therapy has been linked to poor outcome.
Although trimethoprim-sulfamethoxazole (TMP-SMX) has
the strongest in vitro activity against S. maltophilia, increasing
resistance rates have been reported in the literature. Despite
these reports, TMP-SMX is still considered the drug of choice
against this organism.2 It has even been suggested that patients
who have serious S. maltophilia infections and are allergic to
sulfa drugs should undergo desensitization in order to be treated
appropriately.4 Other classes of antibiotics such as aminoglycosides and quinolones are not as effective against S. maltophilia.
S. maltophilia, although not considered an aggressive pathogen,
remains an important cause of morbidity and mortality among
immunosuppressed patients. Patients with cancer particularly
those with prolonged neutropenia continue to be at risk of
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infection with this organism. When S. maltophilia infection is
suspected it is important to obtain sensitivity and susceptibility
data and to institute treatment with TMP-SMX when possible.
This organism commonly causes respiratory and catheterrelated infections, however there are rare reports of urinary and
hepatobiliary infections in the literature. When a patient with
hepatobiliary malignancy and biliary tract obstruction presents
with cholangitis or biliary sepsis infection, S. maltophilia should
be considered in the differential of possible pathogens.3
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Histiocytic Sarcoma: A case of a 52-year-old female with
two synchronous primary malignancies at presentation
Ryan D. Gentzler, MD, Daron A. Kahn, MD
Case Report

A 52-year-old female with a past medical history of chronic
obstructive pulmonary disease, coronary artery disease, and
an 80-pack-year smoking history presented to the emergency
room with complaints of right upper extremity weakness and
imbalance while walking for the previous two days. She stated
that the onset was abrupt and progressively worsening to the
point where she could no longer lift her right upper extremity
against gravity. She maintained the ability to move her hand
and grasp, but admitted to decreased strength and decreased
dexterity of her right hand. She denied changes in vision. She
also denied having bowel or bladder incontinence. She has no
known allergies and her only medications included occasional
benzodiazepines for anxiety and acetaminophen/oxycodone
for low back pain. Her family history was notable only for lung
cancer, which was the cause of death of her mother.
On admission, the patient’s vital signs were stable. She was
afebrile, alert, and oriented to person, place, and time. Her
physical exam was notable for profoundly reduced strength rated
at 1/5 in her proximal right upper extremity. Her distal forearm

Figure 2. Axial view of T1 weighted MRI brain demonstrating
left cerebral enhancing mass with surrounding edema
and hand were also reduced at 3/5 intensity. Her sensation
in her right upper extremity was intact and symmetrical. All
reflexes in her upper and lower extremities were 1+.
A CT scan of her head revealed a large enhancing mass in the
left parietal region. The patient was given levetiracetam 500 mg
twice daily for seizure prophylaxis and dexamethasone 4 mg
every 6 hours to reduce inflammation and edema surrounding
the brain mass. A CT scan of the chest, abdomen, and pelvis was
obtained for further workup and staging prior to surgery. This
study revealed cavitating lung masses in the anterior left upper
lobe and posterior right lobe, likely representing synchronous
primary lung malignancies.

Figure 1. T1 weighted Brain MRI at the time of admission
demonstrates a 1.6 x 1.5 x 1.7 cm solid enhancing mass
centered on the left corona radiata with extensive surrounding
vasogenic edema. T1 weighted Brain MRI at the time of
admission demonstrates a 1.6 x 1.5 x 1.7 cm solid enhancing
mass centered on the left corona radiata with extensive
surrounding vasogenic edema.

An MRI of the brain (Figures 1–2) on the same date revealed
a 1.6 x 1.5 x 1.7 cm mass in the left centrum semiovale. After
discussion with radiologists reading the image, the findings
on MRI were concerning for primary CNS lymphoma and
thought to be atypical findings for a metastatic brain lesion.
A bronchoscopy performed the following day found an
endobronchial lesion nearly occluding the left upper lobe, and
biopsy yielded a diagnosis of squamous cell carcinoma.
Given the fact that the read on the MRI was inconsistent with
metastatic disease from a possible lung origin and was more
consistent with a primary CNS lymphoma, we felt it was
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identified dense collections of histiocytes present within reactive
brain tissue. Many of the histiocytes were atypical in appearance
and stained CD68 and CD163 positive, which is consistent with
a diagnosis of histiocytic sarcoma.
The patient initially responded well to steroids and regained
most of the function of her upper and lower extremity and was
discharged from the hospital after the initial workup. However,
she was readmitted in less than one week with progressively
worsening weakness and gait abnormalities and was found to
have a slightly larger mass on imaging studies (Figure 5). Because
of her severe neurological impairment, she was discharged to
inpatient rehabilitation. Due to her functional status, she was
not a candidate for chemotherapy, and she expired from severe
hemoptysis that was likely secondary to erosion of her lung
cancer through a pulmonary artery.

Discussion

Figure 3. Light microscopy of brain lesion biopsy shows
dense collection of histiocytes, many of which are atypical in
appearance. (10x magnification, H and E stain)

The case presented above is noteworthy not only for the unusual
presentation of synchronous primary neoplasms, but also for
the diagnosis of a rare form of non-Hodgkin's lymphoma,
histiocytic sarcoma (HS), which we believe to be a primary CNS
histiocytic sarcoma. Histiocytic sarcoma is a rare malignancy
that makes up less than 1% of all diagnosed non-Hodgkin’s
lymphoma and has mostly been reported only in small series
of case reports. 1 It is a malignancy of hematopoeitic cells
resembling histiocytes but can be confused with similar looking
T- and B-cell neoplasms. An extensive array of antibodies
must be evaluated to differentiate HS from Langerhans Cell
Sarcoma, diffuse large B-cell lymphoma, peripheral T-cell

Figure 4. Atypical histiocyte seen at high power. (100x
magnification, H and E stain)
necessary to proceed with a biopsy of the brain lesion before
initiating treatment for lung cancer. During the course of
the hospital stay, the patient was fortunate to have improved
function of her right arm and her gait returned to normal. She
was discharged with a steroid taper.
The final brain biopsy (Figures 3–4) results were obtained after
discharge and confirmed the diagnosis of a second separate
malignant process involving the brain. Evaluation of the biopsy
in consultation with the pathology department at the NIH
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Figure 5. Axial view of T1 weighted MRI of the brain 24 days
after admission demonstrates a progressively enlarging mass
(measuring 2.0cm x 1.6cm x 1.9cm) and worsening surrounding
edema. This tumor progression is consistent with an aggressive
nature of histiocytic sarcoma.

lymphoma, acute lymphocytic lymphoma (ALL), metastatic
undifferentiated carcinoma, and melanoma.1,2,3 Unlike other
lymphomas, HS usually presents with extranodal involvement.
About one-third of cases present within lymph nodes, and
two-thirds are extranodal at presentation.2 Of the extranodal
cases, about half present with skin lesions, and the other half
with various sites of involvement including the intestinal tract,
and rarely the central nervous system (CNS).2,4,5 HS is usually
an aggressive malignancy that presents with constitutional
symptoms such as fever and weight loss and symptoms related
to organ involvement such as pancytopenia, bowel obstruction,
rash, and subcutaneous nodules.2 When diagnosed, HS is most
often at an advanced clinical stage with high mortality and
little response to chemotherapy. Patients with primary CNS
histiocytic sarcoma described in case reports have expired
within 3 to 8 months of diagnosis from various complications.3,4
Our patient presented with only extranodal involvement of
the CNS, suffered from severe neurological impairment and
survived for one month after her diagnosis was made. Although
she likely died from complications of lung cancer, her functional
status was progressively worsening due to the increasing size of
the histiocytic sarcoma in her brain.
Due to the rarity of the disease and lack of studies to validate
diagnostic criteria, HS is difficult to diagnose. Several markers
used to help diagnose HS are histiocyte-associated antigens, such
as CD68, lysozyme, CD11c, and CD14.2,4 Diagnosis also requires
a lack of expression of other known cell lineages such as B-cells,
T-cells, myeloid cells, follicular dendritic cells, and CD30.4 More
recently, CD163 has been identified as an important factor for
the diagnosis of HS. CD163 is a hemoglobin scavenger receptor
and its expression is limited to neoplasms of monocytic/
histiocytic derivation. It is more specific than other markers
such as CD68. Cao et al. published in 2007 a case of primary
CNS HS and confirmed the importance of distinguishing CD68
and CD163 positive tumors as HS versus other malignancies.6
Before CD163 was identified, HS was more difficult to diagnose
and perhaps overdiagnosed.1 There are several case reports
identifying histiocytic sarcoma as a primary CNS tumor 4,5,
but these reports came before identification of CD163 as an
important factor for diagnosis. The patient presented in the case
above had a primary CNS malignancy that stained positive for
both histiocyte-associated antigen CD68 and histiocyte-specific
CD163 receptor.

Cao et al. also commented that, considering their findings of
mild cytologic atypia and a profound inflammatory componont,
their initial impression was one of a chronic inflammatory
process. 6 Prominent inflammatory infiltrates have been
described in all five of the previously reportedpublished cases
in the literature of primary CNS HS. A chronic inflammatory
process and was on our differential diagnosis in the beginning
as well.6 Interestingly, due to the rarity of the final diagnosis,
which required numerous histochemical stains and second
opinions from pathology departments at other institutions,
the final diagnosis of histiocytic sarcoma was not obtained for
several weeks following the biopsy. During this time, other
possible etiologies for the brain lesion, including infectious
diseases, were ruled outconsidered and eventually eliminated.
There radiographic appearance of CNS lesions is the key to their
differentiation. Features typical of metastatic disease include
multiple lesions, spherical shape, well demarcated borders,
and their location at the gray matter-white matter junction.7
The lesion in this case, although well-circumscribed, was felt
to be uncharacteristic of metastatic disease due to the depth of
location and lack of multiple CNS lesions. Ultimately, it was
this radiographic appearance that lead us to pursue further
pathologic diagnosis.
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Anomalous Origin of Right Coronary Artery
Neerav G. Sheth MD, Siva K. Kumar, MD
Introduction

Anomalous coronary arteries are rare but potentially life
threatening abnormalities of the coronary circulation. Many of
the variations can be benign in nature; however, some may lead
to myocardial ischemia and/or sudden cardiac arrest.1 The most
common anomalies described in the medical literature involve
branches of the left coronary artery, with the left circumflex
artery originating from the right sinus of Valsalva being the
most prevalent. Patients may present at any age with symptoms
ranging from syncope to sudden cardiac death. Here we present
a case of a patient with anomalous right coronary artery
circulation (RCA) who presented with atypical chest pain.

Case Report

A 38-year-old African American male with a past medical history
of hypertension, COPD, and cocaine abuse presented with a
three day history of atypical chest pain. Initial ECG showed
Normal Sinus Rhythm, non-specific ST changes with premature
ventricular contraction and a positive urine drug screen for
cocaine metabolites (Figure 1). He underwent a Cardiac CTA
from emergency room which revealed an anomalous origin of
the RCA approximately 8mm above the sinotubular junction
above the left coronary sinus of Valsalva. Furthermore, the
proximal portion of the vessel traversed between the aorta and
right ventricular outflow tracts (Figure 2). Given the patient’s
anomalous RCA course, cardiothoracic surgery was consulted
for surgical repair of the anomalous vessel. The rationale for
surgical repair is based on a significantly increased risk for sudden
cardiac arrest and myocardial infarction. His particular anatomy
places him at an extremely high risk during exercise secondary
to dilatation of the pulmonary artery and aorta resulting in
compression of the proximal portion of the anomalous vessel
thereby inducing ischemia and ventricular arrhythmia leading

Figure 1. ECG on initial presentation.
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Figure 2. Cardiac CTA showing the anomalous RCA coursing
between the aorta and pulmonary outflow tracts
to sudden death. The patient was taken to the operating room
for a one-vessel saphenous vein aortocoronary bypass to the
RCA at the level of the posterior descending artery (PDA).

Discussion

Splanchnic mesoderm gives rise to all component of a normal
heart. The mesoderm differentiates into the cardiogenic area
that occurs during week 3 of embryogenesis. The cardiogenic
area subsequently forms a pair of endocardial tubes which fuse
to form the primitive heart tube.2 Normal coronary arteries arise
from appropriate differentiation of pleuripotent cells into their

respective anatomic and functional components. Anomalies
of the coronary circulation result from processes that disrupt
the normal differentiation and specialization of the primitive
heart tube.3 In particular, abnormal involution, position of
endothelial buds, or septation of the truncus arteriosis may give
rise to anomalous origin of coronary arteries.4
In general, anomalous coronary arteries can be described as
those able to cause interruptions in coronary blood flow or
significant or major anomalies, and those that do not, also
known as nonsignificant or minor anomalies. Significant
anomalies are exceedingly rare, but are responsible for 0.25% 0.9% of congenital malformations.2,5
With respect to our case, anomalous origin of the right coronary
artery from the left coronary sinus of Valsalva occurs with an
incidence of 0.05% to 0.1% in the general population. 6 While
anomalous coronary arteries occur with low frequency, there
is a high risk of sudden death due to myocardial ischemia
and resultant arrhythmia associated with them. 7 Various
mechanisms have been postulated to cause the aforementioned
ischemia including: Origin in an acute angle and folding or
occlusion caused by the angulation at the point of coronary
artery emergence,8 coronary spasm resulting from its torsion
movement,8 mechanical compression of the anomalous artery
between the pulmonary and aortic trunks during physical
exertion, 5 and an intramural origin of the coronary artery
from within the aortic tunica media.8 The majority of these
complications may be exacerbated during or immediately after
exercise, as exercise leads to compression of coronary arteries
as well as increasing the preexisting angulation of the proximal
portion of the anomalous vessel.9
Clinical presentation of these patients ranges from asymptomatic
for non-significant anomalies to syncope, chest pain, myocardial
infarction and sudden cardiac death in significant anomalies.
Diagnosis of anomalous coronary arteries may be suggested by
echocardiography and a high index of suspicion. Depending on
the course of the anomalous vessel, a nuclear stress test may
reveal regional hypoperfusion abnormalities in the myocardium
supplied by the vessel.15 In the current era, there is also a role
for Cardiac CTA (CCTA) and Cardiac MRA (CMRA) as
non-invasive diagnostic modalities prior to or in lieu of coronary
angiography. A few small studies have shown CMRA to show a
high degree of correlation to cardiac catheterization10 and have
a sensitivity of 88% and a specificity of 100% as compared with
traditional coronary angiography. 11 Similarly, multi-detector
row CCTA has also been shown to accurately depict anomalous
origin of coronary arteries in those with equivocal findings at
cardiac catheterization or echocardiography.12

competitive flow in the graft.13,14 Particularly, if a vessel courses
between the aorta and pulmonary trunks, has a narrow
ostium, or arises from the pulmonary vasculature, it is highly
susceptible to repeated episodes of myocardial ischemia. These
patients would benefit from surgical intervention. Those with
asymptomatic or non-significant anomalous coronary arteries
may be observed and managed clinically.
Our patient did extremely well following a single vessel aorticocoronary bypass grafting to the RCA at the level of the PDA.
He had complete resolution of his presenting chest pain upon
completion of the bypass. He was medically optimized prior to
discharge and had no further symptoms at follow up.
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Treatment of significant anomalies should be guided by the
nature of the anomalous vessel. The vessel may need surgical
reconstruction, decompression, reimplantation in the correct
sinus, or bypass with ligation of the native vessel to eliminate
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The “Great Imitator” Presents with Abnormal
Liver Enzymes

Ikumi Suzuki, MS IV, Nicholas Orfanidis, MD, Stephanie Moleski, MD, Leo C Katz, MD, David Kastenberg, MD
Case Report

Liver enzymes were repeated and demonstrated a progressive rise
in alkaline phosphatase, aspartate aminotransferase (AST), and
alanine aminotransferase (ALT). (Table 1) Additional laboratory
studies revealed a complete blood count within normal limits,
total bilirubin 1.4 mg/dL (0.2-1.2 mg/dL), direct bilirubin 0.5
mg/dL (0.0-0.4 mg/dL), PT 13.3 seconds (normal 11.1-15.5
seconds) with INR 1.0 (normal 0.80-1.21), and PTT 56 seconds
(normal 19- 39 seconds). The initial work-up for abnormal
liver enzymes revealed the following: hepatitis A IgG/IgM
antibody, hepatitis B PCR, hepatitis C PCR, CMV quantitative
PCR, antinuclear antibody (ANA), antimitochondrial antibody
(AMA), anti-liver kidney microsomal (anti-LKM) antibody
were all within normal limits, and ceruloplasmin was 109 mg/dL
(normal 22 - 58 mg/dL). An ultrasound of the liver and biliary
tree was unremarkable.

A 28 year-old male was referred to the gastroenterology clinic
for evaluation of abnormal liver enzymes. Three months prior to
presentation he was evaluated at a local emergency department
for vomiting and upper abdominal pain. He described pain
as epigastric and worse after eating. He denied fever, chills or
changes in his urine. At that time, the patient was not jaundiced
but reported having a rash. Laboratory testing was remarkable
for elevated liver enzymes (Table 1). The patient was advised to
follow up with his primary care physician. Though his symptoms
resolved without medical therapy, liver enzymes obtained a few
weeks later by his primary physician demonstrated progressive
elevation and he was referred to the gastroenterology (GI) clinic
for further evaluation.
At the time of presentation to the GI clinic, the patient reported
a mild sore throat. He denied any recent sick contacts. The past
medical history was significant for a Staphylococcus aureus
(MRSA) infection 6 months prior for which he was successfully
treated with antibiotics. Around the same time, he reports being
HIV negative. Since the course of antibiotics, he had not taken
any medications, herbal supplements, vitamins, or other over
the counter medications, but drank green tea 2-3 times a week.
There was no family history of liver disease. The patient was a
bisexual male, used alcohol occasionally and denied tobacco use.
He had a distant history of inhaled cocaine use, and had never
used intravenous drugs nor had he ever received a transfusion.

A liver biopsy was entertained, but before proceeding an
additional test was ordered based on the history of rash and
pattern of liver enzyme elevation – a rapid plasma reagin (RPR).
The RPR was reactive with a titer of 1:256. A confirmatory
fluorescent treponemal antibody absorbed (FTA-ABS) was
reactive and the patient was diagnosed with secondary syphilis
with hepatic involvement. Upon diagnosis, the patient reported
being informed of negative test results for both syphilis and
HIV approximately 6 months prior to this presentation. He
was treated with 2.4 million units of benzathine penicillin
G intramuscularly. Given the new diagnosis of a sexually
transmitted disease, repeat HIV testing was also recommended
and was negative. As presented in Table 1, the liver enzymes
improved rapidly following treatment.

On physical examination, the patient was a well-developed,
well-nourished African American male who appeared
comfortable. Vital signs revealed a blood pressure of 137/89 and
pulse of 67. There was no scleral icterus, the mouth and oral
pharynx appeared normal, and there was no palpable lymphadenopathy. Cardiovascular and pulmonary exams were normal.
The abdomen was soft with normal bowel sounds, non-tender,
non-distended, and without hepatosplenomegaly, masses, or
dullness at the flanks. Both the rectal and genital exams were
normal. Skin examination revealed no rashes, jaundice, or
stigmata of liver disease.

Discussion

Syphilis is a complex disease caused by the spirochete
Treponema pallidum. More prevalent in the pre-antibiotic era,
this infectious disease remains a global health issue today. The
disease was the leading cause of neurologic and cardiovascular
disease among the middle-aged population at the turn of the 20th
century.1 Many notable figures have been suspected of having
syphilis including Ivan the Terrible, Napoleon Bonaparte and
Ludwig van Beethoven. In modern times, the number of cases of

Table 1. Liver Enzyme History
Initial Presentation
(time 0)

+ 5 weeks

+ 9 weeks

+10 weeks

Post-Treatment
(2 weeks)

Post-Treatment
(8 weeks)

Alkaline Phosphatase
(29-92 IU/L)

448

1198

1412

1538

439

132

AST (7-42 IU/L)

272

184

165

306

63

41

ALT (1-45 IU/L)

502

304

242

328

78

45

Arrow indicates start of treatment
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primary and secondary syphilis in the United States decreased
during the 1990s and reached its nadir in 2000 since reporting
began in 1941. However, recently the reported number of cases
of early syphilis (primary and secondary) in the United States
has begun to rise as demonstrated by an increase from 5,979
reported cases in 2000 to 11,181 in 2007.2 This infection appears
to particularly afflict men who have sex with men (MSM), with
this group accounting for 65% of the cases as of 2007.3
Untreated, this disease can span decades and cause a wide
array of manifestations affecting multiple organ systems, which
accounts for it being referred to as the “great imitator.” It can
present acutely, or chronically with a more indolent course.
Syphilis is typically acquired by contact with a skin or mucosal
lesion, often sexually, but may also be acquired congenitally. The
natural history of syphilis has been well described and progresses
through distinct phases. Primary syphilis is characterized by a
chancre, a painless indurated lesion occurring at the primary
site of inoculation. The time from inoculation to presentation
of chancre is inversely proportional to inoculating dose, but
typically this incubation period ranges from 10 to 90 days.4
About 25 percent of individuals with untreated primary infection
will develop secondary syphilis, usually occurring 2 to 8 weeks
after appearance of the chancre.5 Secondary (disseminated)
syphilis most commonly involves the skin as a maculopapular
rash involving palms and soles; however, the disease can
involve almost any organ in the body. Mucocutaneous, renal,
neurologic, gastrointestinal, hepatic and pulmonary manifestations have all been reported.6 Constitutional symptoms such
as fever, headache, malaise, anorexia, sore throat, myalgias, and
weight loss may be present. As the manifestations of secondary
syphilis subside, the disease enters a latent period. Latent
syphilis is characterized by positive serologies with no clinical
signs of infection. Relapse of secondary syphilis can occur as
late as 4 years after initial contact, but 75 percent of relapses
occur within the first year. Cellular immunity is thought to play
a role in the pathogenesis. About one third of untreated patients
with latent syphilis develop tertiary syphilis in as early as one
year, or as late as 25 to 30 years, after initial infection.5 Tertiary
syphilis presents with symptomatic involvement of the central
nervous system (CNS), cardiovascular system, or the skin and
subcutaneous tissues. CNS findings can include meningitis,
general paresis, tabes dorsalis (disease of the posterior columns
of spinal cord) and meningovascular disease. Cardiovascular
disease mainly involves the aortic root, which can lead to aortic
insufficiency. Gummatous syphilis can manifest as ulceration
on the skin or a mass lesion involving the viscera.5
Secondary syphilis, the diagnosis in the patient we have
described, is an uncommon and often overlooked cause
of hepatitis. 7 Unfamiliarity with the wide-ranging clinical
presentations of secondary syphilis may delay or prevent
diagnosis, unfortunate given the availability of highly effective

therapy. Approximately 10% of patients with secondary syphilis
may have liver enzyme abnormalities, but clinically apparent
hepatitis is rare.8 The exact mechanism of disease is unknown
but it has been proposed that direct portal venous inoculation
and immune complex-mediated processes may be involved. 9
As in this case, the pattern of liver enzymes found in syphilitic
hepatitis often has a cholestatic pattern with a disproportionate
elevation of alkaline phosphatase and a less prominent elevation
of aminotransferases. One study of HIV-positive patients with
syphilitic hepatitis showed alkaline phosphatase levels ranging
from 234 to 1870 IU/L at time of diagnosis.10 Hyperbilirubinemia
is not commonly seen.11 Liver biopsy, generally unnecessary
if the diagnosis is entertained and appropriate serologic
testing obtained, demonstrates nonspecific findings including
periportal lymphocytic inﬁltration with focal necrosis around
central veins, portal areas, and lobules. Trepenomes or
granulomatous changes are seen in nearly half of cases.12
T. pallidum, the organism responsible for syphilis, cannot be
cultured in a laboratory. The quickest and the most direct
method of diagnosing primary and secondary syphilis is by
direct visualization of exudate from the primary lesion using
darkfield microscopy. This requires specialized equipment
and experienced technicians to recognize the spirochetes. The
use of this method is limited to clinics dedicated to diagnosing
and treating sexually transmitted diseases. An alternative
method of direct spirochete visualization is the use of direct
fluorescent antibody testing (DFA-TP). DFA-TP utilizes
flourescence microscopy to examine specimens incubated with
fluorescein-labeled anti-T. pallidum globulin. This method also
requires specialized equipment and trained personnel which is
not widely availability, and therefore most patients suspected
of having syphilis are diagnosed using an indirect method serologic testing.13 There are two types of serologic tests. The
first type is the nontreponemal test, which detect antibodies
against cardiolipin-cholesterol-lecithin antigens. Examples
are the Venereal Disease Research Laboratory (VDRL) and
the Rapid Plasma Reagin (RPR). Positive results are reported
as an antibody titer, and these tests are relatively inexpensive
and easy to perform. The second type of serologic testing is
specific treponemal tests, which detect antibodies against
the treponemes and/or its cellular components. Examples of
these tests are fluorescent treponemal antibody absorption
(FTA-ABS) test, microhemagglutination test (MHA-TP) and
Treponema pallidum particle aggluitnation assay (TPPA). These
are qualitative tests reported as either reactive or non-reactive.
Nontreponemal tests are 78% to 86% sensitive in primary
syphilis and close to 100% sensitive in secondary syphilis.14 Both
nontreponemal and treponemal-specific tests can be falsely
positive for many reasons including acute febrile illnesses and
immunizations. These test abnormalities typically disappear
within 6 months. Chronic illnesses are also implicated as causes
of false positive testing including autoimmune disorders like
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systemic lupus erythematosus, intravenous drug use, chronic
liver disease and HIV infection. False negative results can also
occur, and this may be seen in as many as 20-30% of patients
presenting with a chancre of primary syphilis.15
Direct visualization techniques, i.e., darkfield microscopy and
DFA-TP, are the only definitive methods of diagnosing early
syphilis. Current recommendations state that use of only one
serologic test is not adequate for making a diagnosis.16 For
screening purposes in those who are asymptomatic, a VDRL
test should be done and those with positive results should
get confirmation using a treponemal test. Nontreponemal
antibody titer is an indicator of disease activity and thus can
be used to monitor disease progress. A four-fold change in
titer is considered clinically significant.16 Contrary to this, a
person with reactive treponeme-specific tests will have lifelong
reactivity even if they are not symptomatic and therefore such
testing is not appropriate for monitoring disease. Any person
with positive treponemal tests should have a nontreponemal
test with titer to assess the status of disease.16
The recommended treatment regimen for adults with primary,
secondary and early latent syphilis is benzathine penicillin G
2.4 million units IM in a single dose. Late latent syphilis or
latent syphilis of unknown duration requires three doses of 2.4
million units IM each at one-week intervals.16 As seen in our
patient, following treatment the liver enzymes rapidly improve
and this response to treatment offers further confirmation
of the diagnosis. All patients should be reevaluated 6 and 12
months after treatment. A four-fold reduction in titer of the
nontreponemal antibody test (e.g., from 1:16 to 1:4) is considered
evidence of an appropriate response. The two nontreponemal
tests (VDRL and RPR) cannot be compared directly, so serial
monitoring should be performed with the same test. Those
without symptomatic improvement or a sustained four-fold
reduction in nontreponemal titers should be retreated.
Early detection is imperative in a disease like syphilis where
definitive treatment is available and devastating permanent
consequences are possible if left untreated. Although a case of
fulminant hepatic failure requiring liver transplant secondary to
syphilitic hepatitis has been reported, patients should not have
any sequelae of chronic liver disease if appropriate treatment is
given.12 Because of the varied presentation of secondary syphilis,
the diagnosis of syphilitic hepatitis should be entertained
in anyone presenting with vague constitutional symptoms
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and acute liver dysfunction with a cholestatic pattern when
obstruction, primary disorders such as primary biliary cirrhosis
and sclerosing cholangitis, and environmental exposure have
been excluded. Clinicians need to have a heightened index of
suspicion for this disease in patients at higher risk for syphilis
including those with HIV infection and MSM in order to
eliminate the need for unnecessary and invasive testing and
offer patients rapid resolution of their disease.
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Use of Transpulmonary Thermodilution to Measure
Extravascular Lung Water Index in a Ventilated Patient
Gunjan L Shah, MD, Susan Ndicu, MD

A 61-year-old morbidly obese woman first presented to a
community hospital with complaints of feeling “unwell” for 2
weeks. Her family reported that she had been having increasing
fatigue, diarrhea, nausea, and vomiting for that period, as well
as “dusky” fingers and toes. Prior to this time, she had noticed
a runny nose, cough, and “bluish” toes for about 3 weeks. On
presentation, she was hypotensive with a systolic blood pressure
in the 50’s mmHg and tachycardic to 115 beats per minute
(bpm), but afebrile. Her creatinine was found to be 12 mg/
dL from an unknown baseline. Treatment was initiated in the
Emergency Department with fluids and antibiotics, and she was
admitted to the Medical Intensive Care Unit for management of
septic shock. The patient was also found to have a urinary tract
infection, with negative blood cultures. Stool was checked for
Clostridium difficile infection, which was also negative. After 7
days of treatment for septic shock in the ICU including 2 days
of hemodialysis, she was transferred to our tertiary center for
further management.
The patient’s past medical history included morbid obesity and
obstructive sleep apnea, but no prior surgeries. Family history
was remarkable for coronary artery disease in her father. She
had no history of tobacco, ethanol or illicit substance use. She
was not on any outpatient medications. Inpatient medications
at the time of transfer included intravenous hydrocortisone,
subcutaneous heparin, esomeprazole, regular insulin sliding
scale and intravenous antibiotics. At the time of transfer, she
was not requiring vasopressor medication support.
Physical examination showed an obese woman who was sedated
and intubated, in no acute distress. She had a temperature of
95.9°F, a heart rate of 108 bpm, a blood pressure of 118/55mmHg,
a respiratory rate of 24 breaths per minute, and an oxygen
saturation of 94%. She had a BMI of 42.3. Notable physical
findings were as follows: coarse breath sounds at bilateral lung
bases, diminished bowel sounds, bilateral upper and lower
extremity edema with cyanotic digits on all extremities and
appearance of necrosis on several toes. She had a peripherally
inserted central catheter (PICC) in the right upper extremity.
Studies on admission included the following: total white blood
cell count of 16,600 with a left shift, hemoglobin of 9.9 g/
dl and platelets 114,000. Chemistries were as follows: sodium
143mmol/L, potassium 3.7mmol/L, chloride 108mmol/L,
bicarbonate 25mmol/L, blood urea nitrogen of 17mg/dl and
creatinine of 4.0 mg/dl. A chest x-ray showed multifocal
consolidation with underlying bilateral pulmonary edema.
On the first day of admission the PICC line removed, and an
internal jugular venous catheter and a femoral artery catheter
were inserted. These were connected to a PICCO® (Pulsion
Medical Systems, Munich, Germany) monitor for measurement
of hemodynamic parameters as well as serial calculation of

Extravascular Lung Water Index (ELWI) via transpulmonary
thermodilution technique. ELWI was from that point onward
calculated serially, and used to direct the amount of intravenous
fluid resuscitation and the use of vasopressors. With
hemodialysis initiated, the ELWI was also used to determine the
amount of fluid volume to be removed at each session. Clinical
and X-ray resolution of the pulmonary edema were in turn
monitored and correlated with the calculated ELWI. Ventilator
settings were adjusted as needed to optimize oxygenation and
ventilation depending on perceived extravascular lung water
content. Other primary and surrogate hemodynamic parameters
recorded included cardiac index (CI), stroke volume index
(SVI), stroke volume variation (SVV), mean arterial pressure
(MAP), systemic vascular resistance index (SVRI), cardiac flow
index (CFI), and global end diastolic volume index (GEDI).

Discussion

Fluid resuscitation in an ICU setting is a complicated affair
because traditional cardiac monitoring does not always
accurately predict fluid responsiveness. 1 Specifically, a fluid
challenge does not necessarily correlate with an increase in
cardiac output (CO), and furthermore may not accurately
reflect the development of pulmonary edema. For this reason,
the measurement of extravascular lung water (EVLW) was
developed. The PICCO system, developed by Pulsion Medical
Systems from Munich, Germany, works by single thermal
indicator transpulmonary dilution.
The main advantage of this system is that it requires only
placement of a central venous and an arterial catheter, avoiding
a pulmonary artery catheter and its associated risks.2 The central
venous catheter and arterial catheter are connected to a pressure
transducer and to the PICCO system. In difficult situations for
catheter placement, such as in patients with a contraindication
to the Trendelenburg position which makes placing a subclavian
or internal jugular venous catheter tricky, the PICCO can still be
used. This is unlike traditional Swan-Ganz catheters. One study
has shown that the EVLW and CO parameters correlated even
with a femoral venous catheter, demonstrating the efficacy of
the PICCO to guide fluid status in patients that have central
access issues.3
After calibration, ice-cold saline (5°C) is injected in three 10mL
aliquots. The femoral arterial catheter measures the change in
temperature through its thermistor tip. The subsequent pulse
contour analysis calculates the area under the curve, the mean
transit time (MTt), and the down-slope time (DSt). The mean
transit time is the amount of time for half of the saline bolus
to pass by the thermistor, while the down-slope time is the
duration of the exponential decrease of the dilution curve.3
Using these measurements, the CO, global end diastolic volume
(GEDV), and intra-thoracic blood volume (ITBV) are calculated
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Table 1. Serial sample readings of the parameters prior to
and after 3 liters of fluid were removed via hemodialysis
Date

2/21/09

2/21/09

Time

845

1645

2.37

2.52

HR (1/min)

63

67

Rhythm

SR

SR

34

37

GEDI (680-800 ml/m2)

760

602

SVV (<10%)

3

10

MAP (mmHg)

111

99

SVRI (1970-2390 dyn*s*cm-5*m2)

3455

2986

4.6

6

12

7

CARDIAC OUTPUT
CI (3-5 l/min/m2)
Frequency

Stroke Volume
SVI (40-60 ml/m2)
Preload

Afterload

Contractility
CFI (4.5-6.5 1/min)
LUNG FUNCTION
ELWI (3-7 ml/kg)
THERAPUTIC INTERVENTION
3L removed via HD
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for earlier detection of pulmonary edema. This is explained by
the fact that when large amounts of liquid are introduced, and
the lung is already edematous, the ice cold water may not have
spread throughout the appropriate volumes assumed in the
above formulas allowing some introduced fluid to be undetected.4
Previous comments about the clinical use of extravascular lung
water have questioned the use of PICCO given that the significance
of detecting small increases in EVLW is unknown.6 We propose
that utilization of PICCO in measuring EVLW in the patient
described above allowed us to clinically decide, in conjunction
with ventilatory status, arterial blood gases, and chest x-rays, the
appropriate time to attempt extubation.
This patient had developed renal failure prior to arriving at
our institution, and as such had negligible urine output while
on dialysis allowing for near complete control of volume
removal. We intervened on her fluid status directly by removing
numerous liters of fluid per dialysis session. After inserting the
PICCO system, our patient’s EVLW was calculated to be 12ml/
kg, correlating with some pulmonary edema, and remained at
this level until 2 liters were removed through hemodialysis.
Immediately following this intervention, the EVLW decreased
to 10ml/kg. Subsequent resuscitation efforts increased this value
again to 12ml/kg. Our solution was to remove 3 liters of fluid
on two subsequent days, decreasing the EVLW to 7ml/kg, or
within normal range. The patient’s chest xray and ventilatory
status correlated with the improved values, and she was then
successfully extubated.

to estimate preload, and EVLW is calculated to indicate degree
of pulmonary edema.2 These hemodynamic values are indexed
to body surface area (BSA) by the DuBois formula2 with body
weight in kilograms and height in centimeters squared. The area
under the curve correlates with the CO.4 Multiplication of the
CO and the DSt gives the pulmonary thermal volume (PTV),
which is the largest individual volume in the series of indicator
dilution mixing chambers. Intra-thoracic thermal volume
(ITTV) is the volume of blood in which the ice-cold water is
dissolved and is calculated by multiplying CO and MTt, which
represents the total volume of the cardiac atria and ventricles
and part of the systemic vascular blood volume or the right and
left atrial end diastolic volumes (RAEDV and LAEDV), the right
and left ventricular diastolic volumes (RVEDV and LVEDV),
and the pulmonary thermal volume.2 Subtraction of PTV from
ITTV represents the GEDV or the total diastolic blood volume
of the heart. Previously, Sakka et al. determined the correlation
of ITBV and GEDV to be 1.25 x GEDV – 28.4(ml).5,6 EVLW can
be calculated via this equation by subtracting ITTV from IBTV.4
Normal values of EVLW are 5-7ml/kg, with values above 10ml/
kg correlating with mild pulmonary edema, and up to 30ml/kg
representing severe pulmonary edema.7

Conclusion

The principle of measuring EVLW rests in the fact that large
increases in EVLW predate the onset of alveolar edema and
symptoms of flooding. One study found that the transpulmonary thermodilution method is actually more accurate in
detecting small rather than large changes in EVLW, which allows

Algorithmic decisions involving diagnosis and treatment of acute
lung injuries are aided by the use of the PICCO system in measuring
EVLW and may allow for the quantification of injury. Though several
studies have not shown a correlation between chest x-rays and
EVLW values,6 we suggest that the volume changes within the lung
may be enough to cause clinical difference even if the radiography
is not significantly different, however formal prospective studies are
necessary to analyze this relationship.
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A 50 Year-Old Homeless Man With Symptomatic
Palpitations
Neerav G. Sheth MD, Daniel R. Frisch, MD
Case Report

The patient is a 50-year old man with Hepatitis C, HIV, and
pneumonia who recently became homeless and presented
with 3 days of worsening palpitations and shortness of breath.
Initially the palpitations were sporadic; however, they had
become more frequent over the three days prior to admission.
He had a corresponding increase in shortness of breath along
with significant decreases in his exercise tolerance. He presented
to the Emergency Department (ED) when he could no long
perform his usual activities of daily living. In the ED, patient
was found to have a narrow complex tachycardia with a rate of
234 beats per minute (bpm) (Figure 1).
His past history is significant for HIV diagnosed in 1979 with
a recent CD4 Count of 16. The patient was not on HAART
medication due to noncompliance resulting from financial
issues. He also has a history of Hepatitis C secondary to remote
intravenous drug abuse. He had pneumonia approximately
three weeks prior to admission, which was incompletely treated
with antibiotics. The patient also noted a 30-pack year history
of tobacco use.
In the ED, the patient was given large volumes of normal
saline followed by 3 sequential doses of adenosine, all of which
failed to terminate his tachycardia. He was then started on
an esmolol infusion with resultant hypotension to a systolic
blood pressure (SBP) of 80mmHg. The esmolol infusion was
subsequently stopped and patient received diltiazem. Following

the diltiazem infusion, the patient still had no decrease in his
rapid heart rate. A cardiology consultation was requested and
procainamide was recommended for chemical cardioversion;
however, the patient’s blood pressure had deteriorated to SBP
of 70mmHg with a heart rate of 240 bpm and the patient was
urgently electrically cardioverted. Sinus rhythm was restored at
a rate of 110 bpm and the SBP improved to 130 mmHg. He was
then referred to the Electrophysiology (EP) service in order to
evaluate for a more durable and definitive management of his
supraventricular tachycardia (SVT). An EP study was performed
and revealed an atrioventricular accessory pathway on the
left lateral mitral annulus that was responsible for his SVT.
The accessory pathway was successfully ablated as evidenced
by intracardiac electrograms and by a lack of initiation of
supraventricular tachycardia following isoproteronol administration after ablation (Figure 2).

Discussion

Supraventricular tachycardia (SVT) is an accelerated rhythm
occurring with a prevalence of 2.25 / 1000 in the general
population with an incidence of 35/100,000 person-years.1
The three most common mechanisms of SVT are atrioventricular nodal reentrant tachycardia (AVNRT), atrioventricular
reentrant tachycardia (AVRT), and atrial tachycardia (AT).
A common feature of all three mechanisms is a narrow QRS
complex (usually identical to the QRS seen in sinus rhythm),
which distinguishes these tachycardias from ventricular

Figure 1. Supraventricular Tachycardia on admission ECG
41

Figure 2. Post Catheter Ablation ECG
tachycardia. Of the three types, AVNRT is the most common,
followed by AVRT. Women more often present with AVNRT,
while men, particularly younger men, are more likely to present
with AVRT.2 AT is more likely to present in patients with
advanced age and/or structural heart disease. While a surface
electrocardiogram can often diagnose which of the three
mechanisms is present,3 an EP study is the gold standard for
diagnosis.
A spectrum of strategies exists for the initial management of
SVT. These include invasive EP studies (i.e. catheter ablation),
noninvasive medical management, and even watchful waiting.
Typically medications (beta blockers, calcium channel blockers)
are used to control the heart rate in SVT. In rare circumstances,
anti-arrhythmic medications such as digoxin and procainamide
can be used as well. However, in all instances of proven SVT,
an EP study with catheter ablation should be considered as a
first-line treatment (ACC/AHA/ESC Guidelines Class I, Level of
Evidence B recommendation).4 This is true even for a patient’s
initial presentation of SVT.
In this case, the patient’s initial presentation of SVT was highly
symptomatic and required urgent care for stabilization and
an expedited EP study with catheter ablation for definitive
treatment. Though it may seem aggressive, this was likely the best
option for this patient. He had been previously non-compliant
with prescribed medications and had an inability to follow up
regularly with physicians, likely due to socioeconomic hardship.
The dilemma posed here is how aggressively to treat this patient’s
first documented episode of SVT. Despite the fact that EP
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studies are invasive and expensive procedures, frequently an EP
study may be more clinically beneficial as well as cost effective.
A single treatment that provides durable benefit is appealing
and is likely to decrease a patient’s burden of disease and health
care utilization for this issue. While ethically we are obligated
as physicians to do what is in the best interest of the patient
without regard to socioeconomic status, we are not immune
from the economic reality of the price tag associated with our
treatments. The initial investment of a relatively aggressive
procedure in this case accomplished the goal of resolving this
patient’s symptoms and addressing the challenge of medical
compliance.
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A Woman With Syncope and Severe, Progressive Headaches
Jennifer Koterwas MS IV, Hind Rahmouni MD, Joanna Kipnes MD
Case Report

A 61 year-old female who was status post-gastrectomy and
chemotherapy for gastric cancer presented to the emergency
department with complaints of two syncopal episodes and
ongoing headaches for the last month. Her syncopal episodes
occurred on the day of admission and five days prior and were
preceded by shaking, dizziness, and a feeling of being in a
“different dimension.” The losses of consciousnesses lasted for
several minutes and were accompanied by shaking, but were not
associated with any urinary or bowel incontinence or tongue
biting. The patient denied any fevers or new medications,
and felt that the episodes were not associated with a specific
activity or time of day. The patient also complained of new
onset headaches that had progressed in frequency over the last
month from being present for only a few minutes a day to being
present for the entire day. The headaches were described as
a “brain freeze,” with 10 out of 10 pain that was not relieved
by acetaminophen with codeine, ibuprofen, or morphine. The
headaches were non-radiating and diffusely located throughout
the head. The headaches were exacerbated by movement, and
associated with an increase in nausea and vomiting. The patient
did not have any lacrimation or rhinorrhea, and she denied any
past history of migraines, head trauma, or neck pain. Review of
systems was negative except for a progressive increase in blurry
vision with occasional white spots in her vision over the last
three weeks. One week prior to admission she had an outpatient
brain MRI (Figure 1a) done, and two days ago a head CT both of
which showed no evidence of metastatic disease, hemorrhage,
infarct, or mass lesion.

normal physical exam, EKG, and echocardiogram. Dehydration
was suspected based on the patient’s orthostatic heart rate
changes and poor dietary intake. Cerebral vasospasm was
thought to be high on the differential for the most likely cause
of her headaches also because of unconcerning imaging and
unusual presentation.
Seizures appeared to be the most likely cause of her loss of
consciousness so an EEG was performed. The EEG revealed
focal slow waves greater on the left mid-temporal region than
the right and frontal intermittent rhythmic delta activity. Fluid
resuscitation was initiated and neurology was consulted to
help with diagnosis and treatment. Following the neurologist’s
recommendation, an MRA of the brain was ordered which
revealed no evidence of cerebral artery stenosis or aneurysms.
As there was no improvement in the patient’s symptoms, a
lumbar puncture was performed on hospital day three which
revealed a non-specific pattern of an elevated opening pressure
of 24 mm H2O, elevated cerebral spinal fluid (CSF) protein
of 114mg/dL, and a normal glucose of 43 mg/dL. On hospital
day six the patient became acutely confused, lethargic, and no
longer oriented to time. Absence seizures were witnessed by the
nurses. Her delirium continued to progress with agitation and

Past medical history was significant for gastric adenocarcinoma
(linitus plastica) status-post gastrectomy 3 months ago and
neoadjuvant chemotherapy with the last dose 3 weeks ago. The
patient was on her fifth week of radiation therapy out of six weeks.
Her current medications included as needed acetaminophen
with codeine, ibuprofen, prochlorperazine, and lorazepam.
On presentation the patient was afebrile with a temperature of
96.4°F, and had a respiratory rate of 18 breaths/minute. She had
orthostatic heart rate changes as demonstrated by an increase
in her heart rate from 87 bpm while supine to 101 bpm while
standing. Her supine blood pressure was 160/100 and her standing
blood pressure was 177/107. She was fully oriented to person,
place, and time. The patient had no nuchal rigidity, nystagmus,
or focal neurologic signs. Her cranial nerves, motor, sensory, and
cerebellar functions were all intact. Reflexes were 2+ bilaterally in
the upper and lower extremities and gait was normal.
The patient was admitted for a workup of syncope associated
with severe, progressive headaches. Intracranial bleeding or
a brain tumor was lower on the differential given the recent
normal head CT and brain MRI. A cardiac etiology was also
unlikely based on the negative history of cardiac disease and a

Figure 1a. Initial MRI of the brain showing no evidence of
metastatic disease, hemorrhage, infarct, or mass lesion.
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new onset hallucinations and delusions. She also developed an
unstable gait, and a new right cranial nerve six palsy. Due to her
rapidly declining condition, dexamethasone was started.
Ophthalmology was consulted to examine the patient’s
visual changes and to evaluate for papilledema due to her
elevated opening pressure on the lumbar puncture. On
exam, a choroidal lesion was detected that was suspicious for
metastasis. The same day, CSF cytology results came back
from the initial lumbar puncture revealing atypical cells highly
suspicious for cancer of an unknown primary. The results of
the lumbar puncture cytology and the suspected metastatic
choroidal lesion prompted a repeat MRI and lumbar puncture.
The results from the repeat MRI revealed increased FLAIR and
enhancement in the subarachnoid space (Figure 1b). The repeat
lumbar puncture revealed an elevated opening pressure of 36
mm H2O, elevated fluid protein of 93 mg/dL, and a low glucose
level of 37 mg/dL, findings which were more consistent with
metastatic cancer. The repeat CSF cytology revealed malignant
cells consistent with metastatic adenocarcinoma (Figure 2).
Both results supported the diagnosis of leptomeningeal carcinomatosis (LC) secondary to linitis plastica adenocarcinoma. The
patient was started on corticosteroids.

Figure 2. CSF cytology revealing epithelial cells with
hyperchromatic and irregularly contoured nuclei, vacuolated
cytoplasms, and high nuclear to cytoplasmic ratios. These
features are consistent with metastatic adenocarcinoma.
On the ninth day of her hospital course and the third day of
steroids, the patient’s mental status markedly improved to
being fully oriented to person, time, and place with only mild
confusion. Her headache also improved and was now present
transiently following her steroid treatments. She was able to
understand her diagnosis and treatment options, and elected
to begin a 5-day course of whole brain radiation followed
by intrathecal chemotherapy. Her mental status returned to
baseline and she was discharged home on hospital day11.

Discussion

Linitis plastica is a poorly differentiated gastric adenocarcinoma
that infiltrates the gastric wall and is commonly associated
with peritoneal and lymph node metastases. Histologically,
linitis plastica is characterized by signet ring cells along with
a marked fibroblastic stroma reaction.3 Interestingly, LC arises
in only 3% to 8% of all solid cancers and most frequently in
patients with leukemia, breast cancer, lymphoma, melanoma,
and lung cancer.1,3 The incidence of LC due to gastric cancer
is 0.06%, although the diagnosis may be on the rise due to an
increased survival time in gastric cancer patients.2,4 Advanced
gastric cancer patients classified as Borrmann type III and IV
which includes linitis plastica, have higher rates of developing
LC when compared to those with early disease. The majority of
patients are diagnosed during the treatment of primary gastric
cancer as seen in our patient.1,7

Figure 1b. MRI of the brain, performed two weeks after
the first MRI, revealing increased FLAIR signal in the sulci
(arrows) and increased enhancement in the subarachnoid
space, suggestive of leptomeningeal carcinomatosis.

44

Extra-abdominal metastasis occurs in less than 13% of gastric
cancer patients with the majority of cases spreading hematogenously to the lung or bone. Although still debated, it is believed
that the Batson’s venous plexus which consists of longitudinally
oriented, valveless paraspinal veins may be the primary route for

tumor cells to reach the subarachnoid space.1,9 Another theory
postulates that the gastric cancer spreads by direct extension
along peripheral nerves to the subarachnoid space. Once the
cancer reaches the leptomeninges and subarachnoid space it
has access to all regions of the central nervous system, leading
to a variety of nonspecific signs and symptoms. LC’s clinical
presentations are variable, ranging from isolated to multiple
central nervous system, spinal, and cranial nerve symptoms
and signs.1 Some common clinical symptoms and signs include
headaches, nausea, vomiting, altered mental status, seizures,
cranial nerve palsie, visual changes, limb weaknesses, and speech
difficulties.3,4 LC is difficult to diagnose not only because of the
variety of presentations, but also because many of the symptoms
resemble common chemotherapeutic induced side-effects, for
example nausea, vomiting, sensory loss, hearing loss, vertigo,
and nystagmus.1,10
Unfortunately there is no single laboratory test or imaging study
that is capable of detecting all cases of LC. Diagnosis for LC rests
on CSF cytology. The sensitivity of a single lumbar puncture
in the detection of atypical cells diagnostic for LC is 54%, but
higher sensitivities can be obtained through repeated tests.4 The
sensitivity of LC increases to 75% after two lumbar punctures,
and up to 85% after three lumbar punctures.6 Other CSF results
suggestive of LC include: increased opening CSF pressure,
increased CSF cellularity, elevated protein CSF content, and
decreased CSF glucose concentration.4 The patient described
in this case study had an increased CSF pressure, increased
protein, and a decreased glucose consistent with the eventual
diagnosis of LC.
The imaging study of choice for leptomeningeal carcinomatosis
is an MRI of the brain, which characteristically shows focal areas
of linear meningeal enhancement in a nodular pattern. The
MRI sensitivity for detecting LC however ranges only from 66%
to 77%. Given the low sensitivity of both CSF cytology and MRI
when used alone, it has been reported that up to 18% of patients
with LC are likely missed.4 The patient described in this case
fell into this category because her diagnosis was missed initially
based on her first MRI. Contrast enhanced CT scans are also
commonly used to evaluate patients but it should be noted that
at most the sensitivity is only 44%.4
Unfortunately, the prognosis of LC secondary to gastric cancer
is poor with a mean survival of four to six weeks for those

who do not receive treatment and a mean survival of two to
six months for those who receive treatment.1,2,4 Some factors
that favor survival are a good performance status, a response
to intrathecal chemotherapy, a low CSF lactate dehydrogenase
concentration, and minimal neurological symptoms.1,7 The
dismal prognosis of LC in the setting of gastric cancer stresses
the importance of early diagnosis because early palliative
treatment may help to improve quality of life. A high clinical
suspicion is necessary to diagnose LC secondary to gastric
cancer due to its nonspecific symptoms, low sensitivity tests,
and rare association with gastric cancer. Therefore, even when
imaging studies are not supportive as in the above case, the
diagnosis of LC should not be ruled out and repeat studies such
as a lumbar puncture should be considered. Although only a few
cases of intraocular metastasis of gastric adenocarcinoma have
been reported, a thorough ophthalmologic exam should also be
considered especially in patients with new-onset visual changes
as it may reveal metastasis (as in this case) and help to expedite
the diagnosis.8
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A Case Report of a Patient With Liver, Psoas Muscle
and Porta Hepatis Abscesses
Eugene Kofi Essandoh, MD
Case Report

A 26-year-old African American male with a history of HIV
and CD4 count of 507 on HAART was sent to the Emergency
Department after a biopsy of a psoas muscle collection
demonstrated pustular drainage. The patient reported that
approximately three weeks prior to presentation he was found to
have elevated liver function tests on routine labs at his primary
care office. Subsequently, the patient was sent for an abdominal
ultrasound and CAT scan which showed a confluence of lymph
node surrounding the porta hepatis as well as a psoas muscle
collection. In review of systems, he reported chronic left-sided
weakness and occasional muscle tightness in both legs. He
denied weakness on the right side, as well as, fevers, chills, cough
or shortness of breath. The physical exams was unremarkable
except for 4/5 weakness in the left lower extremity. Radiographic
imaging (Figure 1) revealed fluid collection in the psoas muscle
and abscesses in the liver and spleen.

A

The patient was admitted to the hospital and started on
vancomycin. His abscess was drained but the culture did not
reveal any organisms. In order to obtain a fluid sample, surgery
performed an exploratory laparoscopy of the fluid collection. The
direct smear showed acid fast bacilli and the PPD demonstrated
induration. Based on these findings, patient was diagnosed with
tuberculosis and started on appropriate therapy.

Discussion

Extrapulmonary tuberculosis (EPTB) refers to tuberculosis
infections of organs other than the lung. Affected patients
usually have a positive tuberculin skin test and a normal chest
x-ray. Tuberculolsis can affect almost all organs. Common sites
of infection include the lymph nodes, liver, spleen, psoas muscle,
adrenal gland, kidney and osteoarticular areas. A resurgence of
tuberculosis in USA occurred in the early 1980’s which coincided
with the emergence of HIV/AIDS. Though the incidence of the
disease is in decline in the US, the global prevalence of the disease
is estimated at 32%. The pattern of the disease has changed
over the years. Reports demonstrate an increased incidence of
disseminated and extrapulmonary TB associated with HIV/
AIDS as well as other immunosuppressed disease-states.1
The diagnosis of extrapulmonary TB especially without
concomitant pulmonary TB can be elusive. It requires a high
index of suspicion based on the patient’s history and risk factors.
Clinical clues that should increase suspicion for EPTB are
ascites with lymphocyte predominance and negative bacterial
cultures; chronic lymphadenopathy; HIV infection; unexplained
pericardial effusion or calcification; CSF lymphocytes with
elevated protein and low glucose; and exudative pleural effusion
with numerous lymphocytes and negative bacteria. A negative
acid-fast smear does not exclude the diagnosis. Extra diagnostic
tests such as a biopsy or PCR may be necessary in the diagnosis
of certain types of EPTB.2

B

Figure 1. A: Psaos muscle with fluid collection
B: Spleen and liver with abscesses
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Musculoskeletal involvement accounts for approximately 35%
of cases of EPTB. It mostly affects the spine (Pott’s disease)
and sometimes articular joints. Paraspinal and psoas muscles
abscesses can develop through local extension from a spinal
abscess or as a primary site. This group of patients may present
with symptoms of lower extremity weakness and localizing
back pain. A bone, synovial or muscle biopsy for AFB smear
and culture is necessary to make definite diagnosis. Patients
with hepatic tuberculosis presents with abnormal liver function
test. Clinically, they may have symptoms such as right upper
quadrant tenderness, nausea and vomiting. The physical exam
may reveal hepatomegaly.
The adrenal glands are rarely affected and even when they are,
it rarely results in severe adrenal insufficiency. Less than 3% of
TB of the adrenal glands resulted in decreased function of the

adrenal gland.3 Tuberculosis rarely affects the myocardium but
when it affects the heart, it usually results in pericarditis. Seeding
of TB in the brain can produce meningitis and tuberculomas. In
a study involving TB patients, about 1 out of 5 was found to have
TB meningitis or tuberculomas.2
In terms of the lymphatic system, TB most commonly affects
the cervical nodes. However, axillary, inguinal, mediastinal
and mesenteric nodes can be affected as well. Lymph nodes
in symptomatic patients are firm, nontender and discrete but
gradually evolve into fluctuant nodes. Diagnosis is made by
excision biopsy with AFB staining or culture. FNA has a low
yield in immunocompetent patients. One can also perform PCR
on a lymph node aspirate.
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A Case Report of a Pheochromocytoma Presenting With
Neurological Manifestations
Nazia Shamsuddin, MD, Whitney Jackson, MD
Case Report

A 51 year-old Caucasian female with a past medical history
of hypertension, coronary artery disease and cerebrovascular
accident presented to the emergency room with acute onset
dysarthria and right-sided hemiparesis. The patient reported
that she noticed these symptoms when she woke that morning,
but had resolved by the time she reached the emergency room,
an hour later. She denied experiencing palpitations, headache,
chest pain or shortness of breath.
On review of systems, it was revealed she had intermittent
nausea and vomiting for a year with increasing frequency over
the past two days. She denied blood or bile in the emesis. She
also admitted to a 50-pound weight loss over the past year. Both
esophagogastroduodenoscopy and colonoscopy were normal
within the past year.
Her medical history was significant for coronary artery disease
complicated by two myocardial infarctions the previous year. She
had also suffered from two past cerebrovascular accidents – the
second of which was complicated by hemorrhage and seizure.
Despite several anti-hypertensive medications, the patient’s blood
pressure remained uncontrolled.
On admission, the patient was afebrile, had an elevated blood
pressure of 167/108, pulse of 95 beats/minute, respiratory rate
of 18 breathes/minute, and pulse oximetry of 97% on room air.
Generally, the patient appeared comfortable. Cardiovascular
exam was benign and pulmonary exam revealed decreased
breath sounds bilaterally. Abdominal exam was also benign
with no masses appreciated. Neurological exam was significant
for slight dysarthria, right homonymous hemianopsia, and
right-sided facial droop. Upper and lower extremity strength
testing was significant for weakness at 4/5 strength on the
left side. Comparatively, the patient’s strength was 5/5 in the
upper and lower extremities on the right side. Additionally,
she was hyper-reflexive on the right side compared to the left.
Sensation was intact throughout. These neurological deficits
were consistent with her baseline deficits from past strokes.
CT of the head was significant for an old left middle cerebral
artery stroke, but there was no evidence of an acute process.
A CT of the abdomen was performed in the emergency room,
which revealed an incidental finding of a 6.7 x 5.4 cm right sided
adrenal mass (Figure 1).
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added for additional blood pressure control. The mass was
surgically removed four weeks later.

Discussion

A pheochromocytoma is a tumor that results in excess secretion
of the catecholamines epinephrine and norepinephrine. It arises
from chromaffin cells of the medulla of the adrenal gland, but
it can also be located in extra-adrenal, retroperitoneal, pelvic or
thoracic sites. Diagnosis relies on measurement of plasma levels
of free metanephrines. This test has a high sensitivity (99%)
and specificity (89%)1. Between episodes of catecholamine
release, catecholamine levels may be normal, which is why
the recommended test measures metabolites, rather than the
catecholamines themselves. The sensitivity and specificity of
other tests such as urinary catecholamines are high, but still
less sensitive and less specific than measuring plasma free
metanephrines1.
Although pheochromocytomas are rare, autopsy studies suggest
a higher prevalence. The National Cancer Registry in Sweden
has reported that pheochromocytomas are discovered in two
patients per million people each year2. Interestingly, in autopsy
studies, the prevalence of adrenal masses may be as high as 8%3,
and of these, 4.2% are diagnosed as pheochromocytomas1.
Due to its variable clinical presentation, pheochromocytomas
have been called “the masquerader”. Retrospective studies show
that of people with pheochromocytomas at time of autopsy, 61%
had a history of hypertension and 91% had a history of “typical”
symptoms, generally considered to be headaches, palpitations
and sweating, but atypical symptoms have also been described.
These atypical symptoms include: abdominal pain, nausea,
vomiting, and dyspnea. Causes of death in people diagnosed
with pheochromocytoma incidentally at time of autopsy include:
myocardial infarction, cerebrovascular accident, arrhythmias,
shock, renal failure and dissecting aortic aneurysm 2. The
catecholamines released by pheochromocytomas can lead to
heart failure, pulmonary edema, arrhythmias, and intracranial
hemorrhage. A pheochromocytoma presenting with cerebrovascular injury is rare and the incidence is unknown.

The laboratory work-up revealed elevated catecholamines:
plasma norepinephrine of 41.6, plasma metanephrine of 27.2,
fractionated urine norepinephrine of 9390 and fractionated
urine metanephrine of 8231.

There are two proposed mechanisms for neurological injury
resulting from a pheochromocytoma: hypertension and
vasospasm. During excess catecholamine release, high blood
pressure may overwhelm cerebrovascular autoregulation
leading to hypertensive encephalopathy. The second proposed
mechanism suggests that catecholamine excess or sympathomimetics cause spasm of the cerebral arteries. These vascular spasms
can cause infarction or transient impairment of circulation4,5.

Diagnoses of transient ischemic attack and pheochromocytoma
were made. Her blood pressure medications were changed to
the alpha-blocker, phenoxybenzamine. A beta-blocker was later

Management of cerebrovascular injury involves inhibiting the
effects of the released catecholamines, epinephrine and norepinephrine. When these hormones are released, epinephrine

Figure 1. CT scan of the abdomen showing 6.7 x 5.4cm adrenal mass.
acts on alpha and beta adrenergic receptors while norepinephrine acts on the same receptors, except b2 adrenergic
receptors. The cumulative effect is potent peripheral vasoconstriction by alpha receptor agonism and increased heart rate
by b1 agonism6. Thus, management of hypertension due to
a secondary cause like pheochromocytoma is very specific.
Pre-operative medical management includes initial alpha
antagonism followed by beta antagonism. Of importance, an
alpha blocker such as Phenoxybenzamine is recommended
approximately 2 days before starting beta-blockade agents7. The
rationale is that beta-blockade alone would result in blocking of
beta receptors that cause peripheral vasodilation, leaving alpha
mediated peripheral vasoconstriciton unopposed. Additionally,
Metyrosine, a competitive inhibitor of the enzyme needed for
catecholamine synthesis, has been proposed for pheochromocytoma management but is rarely clinically utilized at this time6.
Definitive treatment of a pheochromocytoma is surgical removal,
which is curative in up to 90% of cases1. Prior to surgery, the
patient’s clinical status is optimized with blood pressure control
and volume repletion to avoid the consequences of the stress

response from anesthesia and the surgery itself, which could
involve a massive release of catecholamines.
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Idiopathic Ventricular Tachycardia Associated With
AV Reciprocating Tachycardia
Charles-Lwanga K. Bennin, MD, Avinash Chandra, MD
Case Report

A forty-six year old female patient with a medical history of
asthma and seasonal allergies presented with a two day history
of shortness of breath, associated with palpitations. She denied
chest pain or diaphoresis. Patient reported past history of similar
complains that usually lasted less than two minutes and were
relieved with aspirin. The longest episode of palpitations lasted
approximately twenty minutes.
Her social history was significant for tobacco and alcohol
abuse, but negative for substance abuse. Her family history was
significant for cardiovascular disease.
Pertinent findings on physical examination were significant
for elevated blood pressure at 156 mmHg/112 mmHg and
tachycardia at 112 beats per minute. Her electrocardiogram
(EKG) showed tachycardia at a rate of 150 beats per minute
with a long RP interval concerning for atypical AV reciprocating
tachycardia (AVRT). The EKG also revealed right bundle branch
block with a left axis deviation (Figure 1) and non-sustained
ventricular tachycardia (Figure 2) indicating a diagnosis of
idiopathic ventricular tachycardia. A urine drug screen was
positive for cocaine.

Discussion

Idiopathic fascicular ventricular tachycardia has been reported
in literature by Cohen in 19721 and Zipes in 19792. These electro-

physiologic findings are unique in that the QRS complexes are
narrow, especially when compared to the typical wide QRS
complex ventricular tachycardia and a right bundle branch
morphology. The fascicle activated on re-entry determines the
axis - left axis deviation (left posterior fascicle) and right axis
deviation (left anterior fascicle). Some case have been reported
of familial presentations of idiopathic ventricular tachycardia.3
Eighty percent (80%) of idiopathic ventricular tachycardia
originates from the ventricular out flow tracts or the coronary
cusp.4 The origin of these arrhythmias has been attributed to the
posterior inferior left ventricle in a region of the left posterior
fascicle.5 This region probably has a high degree of reentrant or
triggered automicity.6 The adjacent posterior left bundle branch
may or may not be involved in the anterograde limb of the
reentrant circuit.7
Idiopathic ventricular tachycardia, having a morphology of
left bundle branch block and right axis deviation, is believed
to originate in the right ventricular outflow tract, but may
arise from the right ventricular outflow tract in about 18%
of cases. 8 According to Francis et al. idiopathic fascicular
ventricular tachycardia has been limited to three subtypes
in order of prevalence; left posterior fascicular ventricular
tachycardia with a right bundle branch block morphology and
superior axis configuration; left anterior fascicular ventricular
tachycardia with right bundle branch block and right-axis

Figure 1. EKG on admission showing right bundle branch block with a left axis deviation.
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Figure 2. EKG on admission showing non-sustained ventricular tachycardia.

deviation configuration; and the rare presentation of upper
septal fascicular ventricular tachycardia with a narrow QRS and
normal axis configuration.6
Nogami also classified idiopathic ventricular tachycardia into
adenosine sensitive, propranolol sensitive and verapamilsensitive fascicular ventricular tachycardia.9 It appears that
fascicular ventricular tachycardia are sensitive to phenylalkylamine class L-Type calcium channel blockers such
as verapamil as have been well described by Belhassen. 10,11
Calcium channel blockers also suppress conduction through
atrio-ventricular (AV) node, and are effective on both AV
reciprocating tachycardia (AVRT) and AV nodal reentrant
tachycardia (AVNRT).
Atrial pacing as well as supraventricular tachycardia has been
shown to induce ventricular tachycardia due to either reentry or
triggered automaticity. It is not uncommon to find co-existing
tachyarrhythmia and a few cases have been reported of
ventricular tachycardia initiated by atrial arrhythmias including
AV reciprocating tachycardia also known as AV reentrant
tachycardia (AVRT).5
Literature search using PubMed with the following keywords
“Idiopathic ventricular tachycardia, AV reentrant tachycardia,
AV reciprocating tachycardia, AVRT” produced 2 articles. One
case series reported seven patients without structural heart
disease in which AVNRT spontaneously triggered VT in three
cases.12 Another case report illustrated a patient with Wolff-

Parkinson-White (WPW) syndrome. Ventricular tachycardia
originating from the right ventricular outflow tract was induced
during isoprenaline infusion. This also led to atrioventricular
reentrant tachycardia (AVRT). This case report was significant
in that the ventricular tachycardia was possibly driven by
catecholamine stimulation13.
In our case report we present a patient with possible cocaine
induced idiopathic ventricular tachycardia and AV reentrant
tachycardia. Cocaine works on by increasing release of norepinephrine and dopamine and blocking reabsorption of norepinephrine, dopamine and serotonin. Cocaine also blocks sodium
channels, thereby interfering with the propagation of action
potentials. The release of catecholamines that occur in cocaine
intake may exacerbate changes in the action potential threshold
and hence stimulate automaticity. Management of idiopathic
ventricular tachycardia includes radiofrequency ablation and
intravenous verapamil.
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A 30 Year-Old Man Infectious Endocarditis and
Cerebrovascular Accident
Neerav G. Sheth, MD, Joseph DeSimone, MD
Case Report

A 30 year old male with a remote history of intravenous drug
abuse (IVDA) and Hepatitis C was admitted in July 2008
with changes in mental status and a new right sided paresis.
According to the family, the patient was in his usual state
of health until approximately 2-3 weeks prior to admission
when he developed headaches, generalized malaise, and fever
to 101 degrees Fahrenheit after swimming in a lake. He was
seen in an outside hospital emergency department, diagnosed
with otitis media and subsequently discharged on prednisone
and ciprofloxacin. The morning of admission, the patient was
found naked, nonverbal, confused and was subsequently taken
again to an outside hospital emergency department where he
was found to have right sided weakness, diagnosed with a new
cerebrovascular accident (CVA) and transferred to TJUH for
further management.

of embolic source of the patient’s CVA. The patient had a
transthoracic echocardiogram which showed a myxomatous
appearing mitral valve with an echodensity near the base
of the posterior mitral valve with vegetations (Figure 3). A
transesophageal echocardiogram revealed a mobile 0.5 cm x 0.5
cm echodensity attached to the posterior mitral valve leaflet as
well as a second 0.9 cm x 0.5 cm echodensity attached to the
anterior mitral valve leaflet (Figure 4). Of note, the patient’s
TEE bubble study revealed patent foramen ovale (PFO), which
is postulated to have contributed to the presence left sided
infectious endocarditis in a patient with IVDA.
Given the patient’s history of IVDA, he was started on vancomycin
for Staphylococcus aureus via a peripherally inserted central
catheter. A few days later, the organism was found to be sensitive
to methicillin and antibiotics were adjusted apropriately.

On admission, the patient was found to have persistent right
sided hemiparesis, a new loud systolic murmur best heard at
the left lower sternal border and petechiae on his calves. Initial
labs revealed a leukocytosis with left shift. His CT scan showed
an acute left MCA territory infarction (Figure 1). A follow up
MRI revealed additional punctuate foci of restricted diffusion
in the right parietal and left occipital lobe (Figure 2), suggestive

Discussion

Figure 1. CT scan showing Hypoattenuation in Left Frontal
and Temporal lobes compatible with Acute Left MCA Territory
Infarct.

Figure 2. MRI showing acute infarct involving left frontal and
parietal lobes in left MCA distribution with punctate foci of
diffusion restriction consistent with embolic phenomena.

Infectious endocarditis (IE) has been described in the medical
literature for over 100 years. Prior to antibiotics, the condition
was uniformly fatal, with a majority of cases diagnosed at
autopsy. It wasn’t until the development of echocardiography
that there was a significant reduction in the morbidity and
mortality and mortality of IE.
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younger patients has resulted in an increase in the median age
of IE patients over the past 40 years.3

Figure 3. TTE showing myxomatous appearance of mitral valve
with vegetation

Independent of age or risk factors, the most common offending
organisms remain the same, with Staphylococcus aureus and
Streptococcus spp. (including viridians, bovis, and enterococcus)
being the most common. They have been associated with both
native and diseased valve endocarditis. Gram negative bacteria
including Haemophilus species (Haemophilus parainfluenzae,
Haemophilus aphrophilus, and Haemophilus paraphrophilus),
Actinobacillus actinomycetemcomitans, Cardiobacterium
hominis, Eikenella corrodens, and Kingella species (HACEK
organisms) have also been described as causes of infectious
endocarditis, particularly in non-IVDA patients. These
organisms have an increased affinity for adherence to native valve
tissue. However, they are much less common in comparison to S.
aureus and Streptococcus spp and are responsible for only 5-10%
of non-IVDU native valve IE cases.4
Those patients that develop IE, with or without prophylaxis,
may present with a wide variety of clinical features. Some may
present with classic signs and symptoms of low grade fevers,
a new murmur, petechiae, Roth spots, Janeway lesions, and
Osler’s nodes. The last three findings are highly specific and
pathognomonic for IE, but have a low rate of occurrence.
Often, some of the features may not be visible at the time of
presentation. Occasionally, some patients, including the one
presented, will present with symptoms of embolic phenomena.
The diagnosis of IE primarily includes clinical and echocardiographic criteria, divided into major and minor criteria (Table
1). Recently, the Duke Criteria were modified to include the
echocardiographic criteria, as well as to distinguish between
definite, probable, and rejected categories (Table 2).

Figure 4. TEE showing large vegetation on mitral valve.
Presently, there are 10-15,000 new cases of IE diagnosed in the
United States each year1 with estimated national incidences
ranging from 1.4 to 6.2 per 100,000.2 Moreover, epidemiology
reports from the early 1990’s, report incidences as high as 11 per
100,000 in the Philadelphia area.1 In particular, IE has become
more a disease of the elderly as over half of all new cases occur
in those over the age of 60.3
This older demographic, in addition to previously noted
conditions of intravenous drug abuse, structural heart disease,
and recurrent bacteremia may have additional risk factors
that predispose them to develop IE. These include patients
on hemodialysis, with indwelling catheters, severe native and/
or artificial valve disease, diabetes, intravenous drug abuse,
and HIV infection. These additional factors, coupled with a
significant decline in rheumatic heart disease as a risk factor in
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Treatment of IE is directed towards the causative organism as
well as the degree of valvular dysfunction. Staphylococcal and
Streptococcal species are usually responsive to intravenous
vancomycin, pencillins or third generation cephalosporins. If
Table 1. Modified Duke major and minor criteria for
diagnosis of Infectious endocarditis [Li, JS, Sexton, DJ,
Mick, N, et al. Clin Infect Dis 2000; 30:633]
Major Criteria

Minor Criteria

1. Blood cultures positive for
typical organisms

1. Predisposing heart lesions

2. positive cultures 12 hours
apart

3. Fever

3. 3 of 3 positive from
different sites
4. Majority of > 3 cultures
positive
5. Echocardiogram positive
for IE

2. IVDA
4. Vascular lesions:
5. Janeway lesions, emboli,
septic infarcts, hemorrhages
6. Immunologic phenomena
Glomerulonephritis,
Osler’s nodes, Roth spots,
Rheumatoid Factor
7. Microbiologic evidence not
meeting major criteria

Table 2. Diagnosis of IE based on modified Duke Criteria
in Table 1 [Li, JS, Sexton, DJ, Mick, N, et al. Clin Infect
Dis 2000; 30:633]
Definite Diagnosis of IE
2 Major OR
1 Major and 3 Minor OR
5 Minor

Possible Diagnosis of IE
Major and 1 Minor OR
3 Minor

Rejected Diagnosis of IE
Firm alternate diagnosis other than IE
Resolution of symptoms with 4 days of Antibiotics
No pathologic evidence of IE
No echocardiographic evidence of IE

there is significant valvular dysfunction, cardiothoracic surgery
consultation is warranted for valve repair and/or replacement.5
Since there is a significant morbidity and mortality associated
with IE, focus has shifted towards prevention in those patients
at increased risk. However, as previously mentioned, the group
of patients “at risk” can encompass a wide array of individuals.
As a result of this broadening category of “at risk” patients, it
was necessary to identify those at high enough risk to warrant
prophylaxis with antibiotics. Recently, the American College of
Cardiology and the American Heart Association in conjunction

with the Infectious Disease Society of America have reviewed
the data on prevention of IE and have subsequently revised the
guidelines regarding antibiotic prophylaxis (Table 3). These
guidelines reflect significant changes from previously published
ones and are based on the evidence for, or lack thereof, the
efficacy of prophylaxis in patients identified as high risk for IE.6
Amoxicillin is the antibiotic of choice for the majority of
patients requiring prophylaxis and is given in a dose of 2 grams
orally approximately 30 to 60 minutes prior to the procedure.
Patients with a documented allergy to penicillins may be given
any of the following 30 to 60 minutes prior to the procedure: 2
grams of cephalexin, 500 milligrams of either azithromycin or
clarithromycin, or 600 milligrams of clindamycin.6
In conclusion, IE is a real but preventable entity once the high
risk patients have been identified. A review of recent data has
greatly narrowed the number of patients considered “high risk”
and has simultaneously limited the instances in which antibiotic
prophylaxis is necessary. However, narrowing the spectrum of
patients in which prophylaxis does not preclude the necessity
of a pre-emptive approach in preventing infectious endocarditis
and its sequelae.
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Table 3. Updated ACC/AHA/ID Society
recommendations for prophylaxis against IE6
1.

Although IE is a serious condition, the efficacy of antimicrobial prophylaxis is uncertain in all but a few select instances. Therefore,
there are no longer any Class I recommendations for IE prophylaxis in patients with valvular heart disease.

2.

Antibiotic prophylaxis during dental procedures would prevent only a small proportion of cases of IE, even if it were 100%
effective.

3.

IE prophylaxis during dental procedures is appropriate only in patients with underlying cardiac conditions associated with the
highest risk for adverse outcomes. These conditions include:
a.

prosthetic valves or material

b.

Prior IE

c.

Unrepaired cyanotic congenital heart disease (CHD) including shunts and conduits

d.

Complete CHD repair within previous 6 months

e.

Complete CHD repair with residual defects

f.

Valve regurgitation secondary to structural abnormalities in cardiac transplant recipients

4.

In such high-risk patients, prophylaxis is appropriate for all dental procedures involving manipulation of gingival tissue or the
periapical region of teeth, or perforation of oral mucosa (Class IIa).

5.

Increased lifetime risk for IE alone is not an indication for antibiotic prophylaxis

6.

Antibiotic IE prophylaxis is no longer indicated in patients with aortic stenosis, mitral stenosis, or symptomatic or asymptomatic
mitral valve prolapse.

7.

Antibiotic IE prophylaxis is no longer indicated in adolescents and young adults with native heart valve disease.

8.

Genitourinary and gastrointestinal tract procedures (transesophageal echocardiography, esophagogastroduodenoscopy,
colonoscopy, etc.) do not warrant IE prophylaxis unless active infection is present.
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65-Year-Old Man with Weight Loss, Anorexia, and
Distal Extremity Numbness
Leigh Van Vranken, MS III, William Kim, MS III, Darren N. Seril, MD, Toshimasa Okabe, MD
Case Report

A 65-year-old Caucasian male with no significant past
medical history presented to the emergency department with
an unintentional 44-pound weight loss over a four-month
period. The weight loss was preceded by fatigue and anorexia,
which had been increasing for approximately eight months.
In addition, he noted numbness and tingling of his hands and
feet that began over the same time period. The patient was
initially treated for depression with sertraline by his primary
care physician. However, his symptoms persisted without
significant improvement. An initial workup at outside hospital
one month prior to presentation included an abdominal CT
scan, which revealed a mass in the pancreatic head suggestive
of a pseudocyst. He was also treated for Lyme disease with a
course of doxycycline based on a rash finding on his left thigh.
Lyme serologies were negative. He denied fever, chills, night
sweats, changes in bowel habits or stool character, dysphagia,
odynophagia, abdominal pain, cough, or shortness of breath.
He also denied focal weakness, changes in speech, or changes in
vision. He has no known drug allergies. Medications included
sertraline for depression, zolpidem and diphenhydramine
for sleep. He denied tobacco or illicit drug use. He drinks
alcohol occasionally. Family history was noncontributory, with
no history of malignancy, neurodegenerative or endocrine
disorders.
On examination, patient was afebrile with normal vital signs.
The patient appeared cachectic. Body-mass index (BMI) was
18.2 (normal range 18.5 to 24.9). Bilateral temporal muscle
wasting was noted. Examination of the oral cavity revealed
poor dental hygiene, black discoloration of the tongue, and
dry mucous membranes. The abdomen was soft, non-tender,
non-distended, with normal active bowel sounds. There was
no hepatosplenomegaly. Skin was dry and showed decreased
turgor. Neurological exam revealed altered sensation in upper
and lower distal extremities, most marked on the feet and
shins. Muscle strength was normal with the exception of mildly
decreased thumb abductor and adductor muscle strength
bilaterally. The knee-jerk and Achilles reflexes were present
but diminished bilaterally. The remainder of the exam was
unremarkable.

diagnosis. Further evaluation for an occult malignancy included
CT scans of the mandibular, neck, thorax, and abdomen. There
was no evidence of solid tumor or lymphadenopathy from these
imaging studies. CEA was 9.6 ng/mL (normal range: 0.0-5.0
ng/mL) and CA 19-9 was less than 1.0 ng/mL (normal range:
0.0-36.0 U/mL). Prostate-specific antigen (PSA) was normal.
The patient was seen in consultation by psychiatry and it was
determined that the patient did not meet criteria for clinical
depression or dementia. He was subsequently tapered off of
sertraline.
Further evaluation of the complaint of distal extremity
numbness and tingling included screens for diabetes, vitamin
deficiency, and occult malignancy. Vitamin B12 level was within
normal limits. There were no signs of chronic inflammation
or multi-organ involvement suggestive of systemic vasculitis.
Paraneoplastic syndrome was also considered in the differential.
Nerve conduction studies (NCS) and electromyography (EMG)
showed impaired nerve conduction, axonal degeneration, and
demyelination of both motor and sensory nerves. These findings
were suggestive of chronic inflammatory demyelinating polyradiculoneuropathy (CIDP).
The patient’s white blood cell (WBC) count was normal to
mildly elevated throughout the hospital course. However,
lymphocytosis (differential: neutrophil 39.2%, lymphocyte
53.8%, monocyte 4.3%) was noted on admission and persisted.
Further evaluation of the peripheral blood smear (PBS) showed
large granular lymphocytosis (LGLs) (Figure 1), possibly
attributable to reactive phenomenon,but a neoplastic process
could not be ruled out.1 Flow cytometry showed a large (37% of
all non-erythroid cells) cluster of CD45 positive cells.2 Electronic
gating analysis revealed expansion of a natural killer (NK) cell

Hospital Course

The initial differential diagnosis for the patient’s unintentional
weight loss included an occult malignancy, chronic infection or
inflammation, malabsorption, and depression. Given the prior
finding of a pancreatic cyst, endoscopic ultrasound with fine need
aspiration (FNA) was performed, which confirmed the presence
of a benign pseudocyst. Esophagogastroduodenoscopy (EGD)
and colonoscopy were performed to assess for malabsorption
and gastrointestinal cancer. Both studies were unrevealing for

Figure 1. Peripheral blood smear showing large granular
lymphocytes (LGL).
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Table 1. Flow Cytometry of peripheral blood lymphocytes.
Marker

Cell type normally expressing thismarker

% cells expressing marker

CD52

Mature lymphocyte

99%

CD2

T cell or NK cell

97%

CD19

B cell

2%

CD20

B cell

3%

CD3

T cells

12%

CD4

Helper & regulatory T cell, macrophage & monocyte

9%

CD8

Cytotoxic T cell & 30-50% of NK cell

3%

CD56

NK cell

79%

Kappa light chain

B cell

77%

population lacking CD8 expression and expressing Kappa
light chain, or a molecule immunoreactive with anti-Kappa
light chain antibody (Table 1). Kappa light chain is typically
expressed by B lymphocytes. The expression of this molecule in
a NK cell population was suggestive of clonal expansion.
To investigate the possibility of leukemia, a bone-marrow
biopsy was performed, revealing normal marrow architecture
with LGLs similar to those observed on PBS. Polymerase chain
reaction (PCR) analysis of the T-cell receptor (TCR) gene
in peripheral blood samples showed a high frequency single
mutation in the TCR-gamma gene, suggestive of clonality.
The patient continued to have a lack of appetite during his
hospital stay, as well as inadequate oral intake to meet his
nutritional needs. He was administered peripheral parenteral
nutrition (PPN) throughout his stay, until a percutaneous
endoscopic gastrostomy (PEG) tube was placed. His hospital
course was otherwise uneventful and he was discharged to
home with PEG tube feeds to supplement his oral nutrition,
and arrangements to follow-up with hematology for further
management of a hematologic malignancy.
Based on the results of his biopsy, the final diagnosis was natural
killer cell large granular lymphocyte leukemia with possible
paraneoplastic peripheral neuropathy.

Discussion

Differential diagnosis for unintentional weight loss with lack of
appetite is broad. In the elderly, common causes of weight loss
include malignancy, depression, and gastrointestinal diseases.
Chronic pulmonary disease and congestive heart failure can
cause involuntary weight loss by producing anorexia and
increasing resting energy expenditure. In addition, medications
such as antibiotics, non-steroidal anti-inflammatory drugs,
and serotonin reuptake inhibitors, as well as socioeconomic
hardships, can cause profound weight loss. The extensive
workup in the present case suggested hematological malignancy
as the cause of weight loss.
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The causes of peripheral neuropathy are also numerous.
Common causes include systemic diseases (i. e. diabetes
mellitus, vasculitis), chronic liver disease, nutritional deficiency,
infections, neoplasms, medications, and toxins. In our case,
the results of NCS and EMG studies were suggestive of CIDP.
CIDP is a chronically progressive or relapsing sensorimotor
disorder with infiltration by lymphocytes and macrophages into
peripheral nerve tissue.3 This is the chronic equivalent of acute
inflammatory demyelinating polyradiculoneuropathy (AIDP)
found in the Guillain-Barré syndrome (GBS). However, unlike
GBS, CIDP is usually idiopathic and lacks a strong association
with an antecedent bacterial or viral infection.4 CIDP may also
be part of a paraneoplastic syndrome associated with solid or
hematologic malignancy.3 In the present case, negative Anti
MAG, normal TSH, and cortisol levels and normal protein
electrophoresis excluded many of the alternative diagnoses.
The occurrence of a peripheral neuropathy in the setting of
a hematologic malignancy offers a plausible etiology for the
patient’s neurologic symptoms (i.e., a paraneoplastic syndrome).
NK-cell leukemia is a disease within a spectrum of disorders
ranging from the indolent “chronic NK-cell lymphocytosis”
to the quickly fatal “aggressive NK-cell leukemia (ANKL)”.
The diagnosis of NK-cell leukemia can be difficult to establish
because of the lack of readily available clonal markers. Although
a subset of NK cells have been shown to express a rearrangement
of TCR-gamma, this marker is not reliably present.6 The natural
history of NK-cell development is incompletely understood. It
is currently believed to originate from a common lymphoid
progenitor in the bone marrow, but it is also reported that
immature thymocytes retain NK-cell potential with an unknown
contribution to the steady state pool of NK-cells.7 In our case,
the expansion of a NK-cell population with a lack of normal
CD8 expression raised the question of clonality. The NK-cell
population also expressed a unique surface marker for non-B
lymphocytes. The marker was either the Kappa light chain or a
molecule containing an epitope that cross-reacts with polyclonal
antibodies to Kappa light chain. This finding was helpful in

establishing clonality of the NK-cell population, given the lack
of reliable NK-cell-specific markers as noted above.
The clinical presentation of NK-cell leukemia typically includes
“B” symptoms (fever, night sweats, weight loss). In addition,
other common findings included anemia, thrombocytopenia,
hepatosplenomegaly, and gastrointestinal involvement. 8 The
complaints of appetite loss and unintentional weight loss
described here represent an indolent and atypical presentation
of NK-cell leukemia. To date there is no effective treatment
for NK-cell leukemia. Although there is a case series reporting
successful allogeneic hematopoietic cell transplantation9, the
role of this modality in the treatment of NK-cell leukemia is yet
to be determined. Most patients with this disorder have a severe
and refractory clinical course.
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Isolated Spontaneous Renal Artery Dissection
Carrie Ng, MS III, Melissa Gitman, MD
Case Report

A previously healthy 37-year-old man presented to an outside
hospital with an acute onset of sharp left lower quadrant pain
that radiated into his groin while mowing the lawn. The pain
was continuous, lasting until the patient presented to the
emergency room of his local community hospital. He denied
any trauma or sudden changes in position. The patient identified
no aggravating or alleviating factors for the pain. The pain was
associated with nausea and one episode of bilious, non-bloody
emesis. He also noted urinary hesitancy but denied hematuria.
The patient’s past medical history was significant for hyperlipidemia, controlled with gemfibrozil, and a 13-pack year smoking
history. The patient presented to a local emergency department
and underwent a CT scan of his abdomen that demonstrated
an anterior left renal infarct due to a suspected thrombosis of
anterior division of the left renal artery.

Figure 1. MRA demonstrating renal infarct.
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On transfer to the VA Hospital for further management, he was
afebrile and normotensive. Physical examination was significant
for an abdomen that was tender to palpation in the left lower
quadrant and left costovertebral tenderness. Laboratory studies
were notable for an elevated white blood cell count of 11 500
per mm3 and a decreased platelet count of 97 000 per cubic
millimeter. His creatinine and blood urea nitrogen were within
normal limits and were 1.0 mg/dl and 20 mg/dl respectively.
During his hospital course, his blood pressure ranged between
128-140/81-84, his Cr remained stable, and he had one episode
of low-grade fever of 100.1°F. A magnetic resonance angiogram
(MRA) was performed on day 2 of hospitalization (Figure 1).

Discussion
Introduction

The differential diagnosis for renal infarct includes embolic
disease, thrombosis of the renal artery, renal artery dissection, and

injury to the renal artery. Injury to the renal artery is responsibly
for more than 75% of renal artery dissections and is generally due
to extension of an aortic dissection, a trauma to the abdomen or
an iatrogenic injury. The MRA the patient underwent on day
two of his hospitalization confirmed the presence of a renal
infarct but showed no focal aneurysm, dissection or stricture.
Several diagnoses were entertained for possible etiologies of the
renal infarct. The initial diagnosis of thrombosis was ruled out
by the absence of clot on review of both the initial CT scan at the
outside hospital as well as the MRA. The MRA failed to identify
any abnormalities in the vasculature and serological studies did
not demonstrate evidence of Polyarteritis Nodosa (PAN) thus
this was felt to be unlikely to be the cause. An echocardiogram
failed to demonstrate valvular vegetation and given the absence
of other signs of embolic disease this diagnosis was ruled out.
The diagnosis in this patient was finally reached by exclusion.
Although the MRA did not demonstrate a dissection it was felt
that, SRAD was the most plausible cause of his renal infarct
given the patient’s history and clinical presentation as evidenced
by the discussion below.
Isolated SRAD is a rare event, with less than 200 reported cases
in literature, and a quarter of those being autopsy findings.1 The
actual incidence is higher than reported because many dissections
are either silent or resolve spontaneously.1,2 As clinically apparent
SRAD is uncommon, there is minimal data available concerning
the optimal management strategy for this condition.

Clinical Features

The etiology of SRAD is often unknown. A few factors have
been identified as risk factors for SRAD including atherosclerosis, fibromuscular dysplasia, connective tissue diseases
and other conditions that might affect the integrity of the renal
artery1. The condition is more common among males, smokers
and generally occurs between the ages of thirty to fifty. Most
patients do not have other underlying co-morbid conditions.
The most common clinical presentation is the acute onset of
severe abdominal or flank pain. Another common finding is
the presence of low-grade fever as seen in our patient. Much of
literature on SRAD describes its clinical presentation as having
severe hypertension and renal insufficiency.1,2 On the conrtrary,
Ramamoorthy et al 5 and Misrai et al 4 suggest that most patients
actually present like ours did with normal blood pressure and
renal function with symptoms of kidney infarction.

While MRA may be useful in making the diagnosis, angiography
is the goal standard and remains the modality of choice as it can
potentially be diagnostic and interventional.1

Treatment

Once a SRAD is diagnosed, there are several options for
treatment including medical, surgical, and interventional
radiology depending on the renal function and lesion
stability. Spontaneous resolution as seen in our case has been
documented and observation or medical management of
hypertension may be sufficient.1,2 Anticoagulation has also been
suggested for medical management although it has not been
demonstrated that this confers any long term benefit1. Surgical
treatments such as vascular reconstruction, and endovascular
procedures such as stenting or coil embolization, have also
described in literature. 1,3 Surgical interventions have been
identified as beneficial in cases where the patient does not have
significant renal ischemia but continues to suffer uncontrollable
hypertension. Vascular reconstruction has been described
as having good long-term results, but post-operatively many
patients still require anti-hypertensives and the procedure has
a high morbidity rate including acute thrombosis of the renal
artery and late anastomotic restenosis.3,4 Revascularization with
stenting is indicated when there is a severely stenotic vessel
that provides blood flow to an ischemic part of the kidney.3 If
patient has an isolated involvement of an accessory renal artery,
then percutaneous embolization is another option. Finally,
nephrectomy is considered when the kidney is already severely
damaged from the infarction or if revascularization would be
not be an option.1,5,6

Conclusion

The available literature suggest that SRAD is a relatively
benign condition and surgical treatment are considered when
patient has failed medical management.5 However, long-term
follow-up of blood pressure and renal function are important
since this condition is generally poorly understood.1 The patient
in this case was managed conservatively with analgesics and
anti-emetics and was discharged home without any sequelae of
his renal infarct.
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Work-up

Diagnostic work-up should include checking a complete blood
count for the presence of leukocytosis, basic metabolic panel to
check renal function, liver function enzymes to rule out other
causes of abdominal pain and a urinalysis for the presence of
red blood cells. The diagnosis is not usually made until it is
detected on radiologic imaging, because the history, physical,
and laboratory findings results are usually non-specific. CT of
the abdomen with contrast is generally the first imaging study
ordered, usually undertaken for suspected nephrolithiasis.
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Coronary Heart Disease and Fish Oil
Talya Spivack, MD
Introduction

The benefits of fish consumption on cardiovascular disease has
been suggested since the early 1980s in studies that demonstrated
Greenland Eskimo’s low rates of death from coronary heart
disease.1 This was followed by another observational study
that demonstrated the same findings in Japan.2 The proposed
linkage between these two groups of people is their propensity
to consume fish. Since then many studies have examined the
relationship between fish consumption and coronary heart
disease (CHD) mortality rates. Current thinking suggests that
the primary benefit of consuming fish is secondary to the
omega-3 fatty acids found in fish oil.16,17

Omega -3 Fatty Acid Sources and Action

Omega-3 fatty acids are long-chain polyunsaturated fatty
acids (18-22 carbon atoms in chain length) with the first of
double bonds beginning with the third carbon atom. Plants
and marine fish are the two main dietary sources of omega-3
fatty acids found in nature. For the purposes of this article,
we will mainly discuss the role of marine omega-3 fatty acids.
These are generally found in oily fish such as mackerel, lake
trout, herring, sardines, albacore tuna and salmon. There are
two types of marine omega-3 fatty acids: eicosapentaenoic acid
(EPA) & docosahexanoic acid (DHA). In the human body, these
are broken down by the enzymes cyclo-oxygenase and then
lipoxygenase to create eicosanoids.
The exact mechanism of action of omega-3 fatty acids on
CHD remains unknown. However, several ideas have been
postulated. Omega-3 fatty acids have been shown to decrease
serum triglyceride concentrations in a dose dependent
relationship by 25-30%.10 Omega-3 fatty acids have also been
linked to decreased platelet aggregation11,12, 6 as well as the ability
to stabilize the myocardium against ventricular arrhythmia in
animal studies.13, 14, 15, 6

The Evidence

One of the first significant prospective trials done demonstrating
the correlation between consumption of omega-3 fatty acids
and coronary heart disease was done in the Netherlands over a
20 year period. Information about the fish consumption of 852
middle-aged men without coronary heart disease was collected
by a careful dietary history obtained from the participants and
their wives. During 20 years of follow-up 78 men died from
coronary heart disease. An inverse dose-response relation was
observed between fish consumption in 1960 and death from
coronary heart disease during 20 years of follow-up. Mortality
from coronary heart disease was more than 50 % lower among
those who consumed at least 30 grams of fish per day than
among those who did not eat fish. It was concluded that the
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consumption of as little as one or two fish dishes per week may
be of preventive value in relation to coronary heart disease.3
The Netherlands study was shortly followed by the Diet and
Reinfarction Trial (DART) of 1989. This was a randomized
control trial with factorial design performed with the intent
to examine the effect of dietary intervention in secondary
prevention of MI. The major endpoints of the study were total
mortality and ischemic heart disease events (IHD events and
nonfatal MI). Men enrolled in the trial were weighed, measured,
and randomly assigned to receive or not receive dietary advice
on three factors. The first factor was total fat intake. The men
in this arm were designated to reduce fat intake to 30% of total
energy and to increase the polyunsaturated/saturated fat ratio
as much as possible. The next arm was the fish arm. Men were
told to consume at least two weekly portions (200-400 g) of fatty
fish (mackerel, herring, kipper, pilchard, sardine, salmon, and
trout). Men who could not tolerate fish were given the option of
taking three fish oil capsules per day, providing a total of 900 mg
EPA and DHA. The next arm of the study examined fiber intake.
These men were instructed to increase their intake of cereal
fiber to 18 g daily. Weight reduction advice and smoking advice
were given as seen fit to all arms of the study. The results were
surprising. The fish oil arm was shown to have the most CHD
benefit demonstrated by an overall reduction of cardiovascular
disease mortality by 29%. Surprisingly, the overall dietary fat
group did demonstrate a significant decrease in the number of
MIs suffered but did not show any overall benefit in mortality.4
The next large randomized control study to demonstrate a
similar benefit was The Indian Experiment of Infarct Survival
published in 1997. This randomized placebo controlled trial
aimed to test the effect of fish oil and mustard oil supplementation versus placebo on complications and cardiac events
in patients with prior suspected acute myocardial infarction
during a follow-up period of 1 year after symptoms were
first experienced. Participants were randomized to fish oil (6
capsules per day, providing approximately 2 g of omega-3 fatty
acids), mustard seed oil (a source of a-linolenic acid, 2.9 g/d
provided in 20 mL of oil), and placebo (aluminum hydroxide,
100 mg). After one year, total cardiac events were 25% and 28%
in the fish oil and mustard oil groups, respectively, versus 35%
in the placebo group.5, 6
The success of the DART trial and the Indian Experiment
of Infarct Survival trial spawned the Gruppo Italiano per lo
Studio della Sopravvivenza nell’Infarto miocardico (GISSI)
trial in 1999. This trial was a secondary prevention clinical trial
designed to assess the effects of omega-3 polyunsaturated fatty
acid and vitamin E supplementation on mortality and recurrent
events in patients with recent MI. The study randomized 11,324

patients who had survived a myocardial infarction within the
last 3 months to four arms: omega-3 fatty acid group received
one capsule per day of a highly concentrated product containing
about 850 mg of EPA and DHA, the vitamin-E group received
300 mg/d of synthetic a-tocopherol, the combined treatment
group received both, and the control group received neither.
The GISSI trial was the first demonstration that a pharmaceutical preparation of omega-3 fatty acids in addition to
dietary and other accepted interventions has a favorable effect
on clinical endpoints in post-MI patients. Another unexpected
finding was those taking the omega-3 fatty acids experienced a
20% reduction in overall mortality and a 45% decrease in risk
for sudden cardiac death.7,8
One of the confounders of the above randomized control
trials was that the trials had only included men. As a result,
a retrospective analysis relating coronary artery disease and
fish oil was performed on the cohort of female patients used
for the Nurse’s Health Study. The end point for this study was
incidence of CHD including CHD deaths and nonfatal MI.
Women were divided into 5 categories based on frequency
of fish consumption: <1 serving per month, 1-3 servings
per month, 1 serving per week, 2-4 servings per week, and 5
servings per week. This trial showed a stepwise decrease in all
arms related to more fish consumption in total coronary heart
disease cases, fatal coronary heart disease events, and nonfatal
MI.9 Although this study is convincing, it is also limited by the
inability to control for the fact that people who consume more
fish products may have an inherently healthier lifestyle.

Conclusions

The physician must weigh the risks and benefits of prescribing
fish oil to their patients. It is important to realize the antiplatelet
effects and theoretical ramifications in using omega-3 fatty
acids therapeutically in patients with bleeding tendencies. In
addition, pregnant and nursing woman must be cautioned
against consuming certain fish such as shark, swordfish, golden
bass, and king mackerel that have a higher proportion of
mercury. Studies suggest that prenatal mercury exposure can be
detrimental to neurological development in children.18,19
In 2002, the American Heart Association (AHA) published
guidelines advocating the use of omega-3 fatty acids in patients
with and without documented CHD. In patients without CHD
they recommended eating a variety of (preferably oily) fish at
least twice a week. In patients with CHD they recommended
consuming approximately 1 gram of EPA and DHA daily,
preferably from oily fish. In addition they suggested that in
this patient population fish oil capsules could be considered in
consultation with physicians. In the patients needing triglyceride
lowering the AHA recommended 2 -4 grams of EPA and DHA
daily provided as capsules under a physicians care.6
Omega 3 fatty acids have been shown in epidemiological studies
and randomized control studies to decrease the incidence of

coronary heart disease both in patients with existing coronary
heart disease and prospectively. Although more studies are
needed to examine the exact mechanism of action of omega-3
fatty acids, studies do show a substantial benefit related to the
increase of intake of fish oil, both in capsule form and through
dietary sources. In conclusion, evidence suggests recommending
omega-3 fatty acids to patients at risk for and who have suffered
from cardiovascular heart disease.
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Recipes
Jeff Chef 2009 Winning Recipes
EntrÉe
Sanjay Mama’s Lamb Curry
Ingredients
3-4	lbs leg of lamb cut into
1.5 inch cubes, fat
trimmed off as much as
possible (usually need
to start with 7 lb
bone-in leg of lamb and
have butcher cut it for
you, can save some of
the bone to cook in the
curry)
+
Several tbsp peanut oil
2
cups whole canned
tomatoes
8
garlic cloves
2/3
cup plain yogurt
31/2
cup chopped Spanish 		
onion
16
cardamom pods
16
cloves
4
tsp turmeric
2	tsp red chili powder
4	tsp kosher salt
11/2
tsp cumin
+
fresh cilantro
6
cups hot water

Lindsay Bischoff, MD
Preparation

1. Preheat oven to 325 degrees F
2. In a blender/food processor blend tomatoes, garlic, ginger, yogurt until smooth. Set
aside.
3. Heat 1-2 tbsp oil in very large pot and brown lamb cubes on all sides but do not
cook through. Remove from pot and set aside.
4. In same pot, caramelize onions in 1-2 tbsp oil for about 20min. Add cumin, chili
powder, turmeric, salt, cardamom, and cloves. Cook for about 1 min.
5. Add puree (see above) to onions and spices and cook for about 5-7min covered but
occasionally letting steam out.
6. Add meat and 6 cups of hot water. Mix and bring to boil. Once boiling, place in oven
(at 325°) for 2 hours. The pot should be covered with foil first, then the lid placed on
top. Take out to stir every 30 min. Removed from oven after 2 hours. Stir.
7. Turn oven off and place back in oven for 15 minutes. Remove from oven.
8. Place in bowls, garnish with fresh cilantro. Serve with basmati rice and plain yogurt
(if too spicy).
Yum!

Dessert
Banana White Chocolate Coffee Cake
Ingredients

33/4	cups all-purpose flour

tsp baking soda
1
tsp salt
2
sticks unsalted butter,
melted
1
cup granulated sugar
1
/2
cup firmly packed
brown sugar
2
large eggs
3
tbsps dark rum
1
tsp vanilla extract
4
large ripe bananas,
mashed
1	cup shredded coconut
1
cup (6 ounces) white
chocolate chips or chunks
Glaze
1
/2
cup (3 ounces) white
chocolate chips or chunks
1
/3
cup unsalted butter
1
Tbsp whipping cream
11/4
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Dana Marrero, MD

Preparation

1. Preheat the oven to 350 degrees F. Butter and flour a 10 inch bundt pan.
2. Sift together the flour, baking soda and salt and set aside.
3. With an electric mixer, mix together the butter, sugar and brown sugar until blended.
Over low speed, add the eggs, one at a time and beat until blended. Add the rum and
vanilla and continue to beat, over medium speed for 5 minutes. Add the bananas and
beat until blended. Over low speed, slowly add the flour mixture until just blended. If
you overmix once the flour is added the batter will become tough.
4. With a wooden spoon, fold in the coconut and white chocolate. Pour into the prepared
pan, smoothing the top with a spatula. Bake for 50 minutes, or until a toothpick
inserted in the middle comes out clean. Cool in the pan for 15 minutes before
removing to a serving plate.
5. To make the glaze: In the microwave melt together the chocolate chips, butter and
cream. Whisk until blended and drizzle over the cake.
Bon Appétit!
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